<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001168" GROUP_ID="ORAL" ID="712699072012132795" MERGED_FROM="" MODIFIED="2011-06-15 13:21:31 +0200" MODIFIED_BY="Philip Riley" REVIEW_NO="0017" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-06-15 11:58:40 +0100" MODIFIED_BY="Philip Riley">
<TITLE>Interventions for treating oral lichen planus</TITLE>
<CONTACT>
<PERSON ID="A08D03D482E26AA20165AC2EAD62B8C7" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Kobkan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thongprasom</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Oral Medicine</POSITION>
<EMAIL_1>Kobkan.T@Chula.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine, Faculty of Dentistry</DEPARTMENT>
<ORGANISATION>Chulalongkorn University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bangkok</CITY>
<ZIP>10330</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+66 2218 8935</PHONE_1>
<PHONE_2/>
<FAX_1>+66 2218 8818</FAX_1>
<FAX_2>+66 2218 8941</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-06-15 11:58:40 +0100" MODIFIED_BY="Philip Riley">
<PERSON ID="A08D03D482E26AA20165AC2EAD62B8C7" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Kobkan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thongprasom</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Oral Medicine</POSITION>
<EMAIL_1>Kobkan.T@Chula.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine, Faculty of Dentistry</DEPARTMENT>
<ORGANISATION>Chulalongkorn University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bangkok</CITY>
<ZIP>10330</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+66 2218 8935</PHONE_1>
<PHONE_2/>
<FAX_1>+66 2218 8818</FAX_1>
<FAX_2>+66 2218 8941</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A086F8C582E26AA20165AC2EC6742787" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Marco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Carrozzo</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Oral Medicine</POSITION>
<EMAIL_1>marco.carrozzo@ncl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine, School of Dental Sciences</DEPARTMENT>
<ORGANISATION>University of Newcastle upon Tyne</ORGANISATION>
<ADDRESS_1>Framlington Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Newcastle upon Tyne</CITY>
<ZIP>NE2 4BW</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 191 222 6797</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="50BB1C5582E26AA20094E4F45CBA083C" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Furness</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>Susan.Furness@manchester.ac.uk</EMAIL_1>
<EMAIL_2>suefurness@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6877</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18367" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lodi</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>giovanni.lodi@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unit of Oral Pathology and Oral Medicine</DEPARTMENT>
<ORGANISATION>Department of Medicine, Surgery and Dentistry, University of Milan</ORGANISATION>
<ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20142</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 50319021</PHONE_1>
<PHONE_2/>
<FAX_1>+39 02 50319041</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-06-14 09:59:15 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="7" MONTH="6" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="1" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="7" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2011-06-14 10:12:26 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-14 10:11:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Searches updated to 26 January 2011.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-06-14 10:12:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Significant update of original review published in 1999: new review team; review methodology updated; included studies increased from 9 to 28.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-06-14 09:59:54 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-14 09:59:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-06-14 18:10:09 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-06-14 18:10:09 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-06-14 18:10:09 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Oral Health Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Provided funding support for a group meeting to be held in Milan, Italy, from 7th to 11th July 2009</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-06-15 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-06-15 10:58:40 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-06-14 10:27:05 +0100" MODIFIED_BY="[Empty name]">Interventions for treating oral lichen planus</TITLE>
<SUMMARY_BODY MODIFIED="2011-06-15 10:58:40 +0100" MODIFIED_BY="[Empty name]">
<P>Oral lichen planus (OLP) is a condition where there are long-term, painful areas on the lining of the mouth. The treatment is for reducing pain but there is no cure for this disease. Usual treatment is steroid ointment applied directly to the painful areas. This review found no research evidence to show that one type of steroid is better or worse than another. There is no evidence that a group of treatments called calcineurin inhibitors (e.g. pimecrolimus) are more effective than placebo. This review found that aloe vera may reduce pain and clinical signs of OLP.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-06-15 11:27:18 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-06-14 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Oral lichen planus (OLP) is a common chronic autoimmune disease associated with cell-mediated immunological dysfunction. Symptomatic OLP is painful and complete healing is rare.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-06-14 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness and safety of any form of therapy for symptomatic OLP.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-06-10 11:25:18 +0100" MODIFIED_BY="Anne Littlewood">
<P>The following electronic databases were searched: the Cochrane Oral Health Group Trials Register (to 26 January 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 1), MEDLINE via OVID (1950 to 26 January 2011) and EMBASE via OVID (1980 to 26 January 2011). There were no restrictions regarding language or date of publication.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-06-14 10:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled clinical trials (RCTs) of therapy for symptomatic OLP which compared treatment with a placebo or between treatments or no intervention were considered in this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-04-04 16:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts of all reports identified were scanned independently by two review authors. All studies meeting the inclusion criteria were assessed for risk of bias and data were extracted. For dichotomous outcomes, the estimates of effects of an intervention were expressed as risk ratios (RR) together with 95% confidence intervals. For continuous outcomes, mean differences (MD) and 95% confidence intervals were used to summarise the data for each group. The statistical unit was the patient. Meta-analyses were done only with studies of similar comparisons reporting the same outcome measures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-06-15 11:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>28 trials were included in this review. Pain is the primary outcome of this review because it is the indication for treatment of OLP, and therefore this review indicates as effective, only those treatments which significantly reduce pain. Although topical steroids are considered first line treatment for symptomatic OLP, we identified no RCTs that compared steroids with placebo. There is no evidence from the three trials of pimecrolimus that this treatment is better than placebo in reducing pain from OLP. There is weak evidence from two trials, at unclear and high risk of bias respectively, that aloe vera may be associated with a reduction in pain compared to placebo, but it was not possible to pool the pain data from these trials. There is weak and unreliable evidence from two small trials, at high risk of bias, that cyclosporin may reduce pain and clinical signs of OLP, but meta-analysis of these trials was not possible.</P>
<P>There were five trials that compared steroids with calcineurin inhibitors, each evaluating a different pair of interventions. There is no evidence from these trials that there is a difference between treatment with steroids compared to calcineurin inhibitors with regard to reducing pain associated with OLP. From six trials there is no evidence that any specific steroid therapy is more or less effective at reducing pain compared to another type or dose of steroid.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-06-15 10:09:31 +0100" MODIFIED_BY="[Empty name]">
<P>Although topical steroids are considered to be first line treatment, we identified no RCTs that compared steroids with placebo in patients with symptomatic OLP. From the trials in this review there is no evidence that one steroid is any more effective than another. There is weak evidence that aloe vera may reduce the pain of OLP and improve the clinical signs of disease compared to placebo. There is weak and unreliable evidence that cyclosporin may reduce pain and clinical signs of OLP. There is no evidence that other calcineurin inhibitors reduce pain compared to either steroids or placebo. From the 28 trials included in this systematic review, the wide range of interventions compared means there is insufficient evidence to support the effectiveness of any specific treatment as being superior.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-06-15 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-06-14 18:07:01 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-06-14 10:38:29 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Lichen Planus (OLP) is a common chronic inflammatory disease associated with cell-mediated immunological dysfunction (<LINK REF="REF-Thornhill-2001" TYPE="REFERENCE">Thornhill 2001;</LINK> <LINK REF="REF-Lodi-2005a" TYPE="REFERENCE">Lodi 2005a</LINK>). The prevalence of OLP has been reported as 1.27% and it is more frequently seen in women aged between 30 and 60 years (<LINK REF="REF-McCartan-2008" TYPE="REFERENCE">McCartan 2008</LINK>). Clinical appearances present in various manifestations such as reticular, papular, plaque, atrophic and ulcerative (erosive) patterns (<LINK REF="REF-Lodi-2005a" TYPE="REFERENCE">Lodi 2005a</LINK>). The reticular lesion is the most common form of OLP which appears as a network of overlapping white striae, followed by ulcerative (erosive), atrophic and plaque (<LINK REF="REF-Escudier-2007" TYPE="REFERENCE">Escudier 2007</LINK>). Reticular OLP is often asymptomatic but the atrophic and ulcerative (erosive) forms of OLP can cause symptoms ranging from burning sensation to severe pain with remission being rare (<LINK REF="REF-Carrozzo-1999" TYPE="REFERENCE">Carrozzo 1999;</LINK> <LINK REF="REF-Eisen-2002" TYPE="REFERENCE">Eisen 2002</LINK>). OLP commonly occurs bilaterally on the buccal mucosa, and frequently appears in the tongue, gingiva, mucobuccal fold or multiple sites.</P>
<P>The oral manifestations of OLP may be sufficient to make a correct diagnosis. However, oral biopsy with histopathological evaluation is recommended to confirm the clinical diagnosis and to exclude dysplasia and malignancy (<LINK REF="REF-Eisen-2005" TYPE="REFERENCE">Eisen 2005;</LINK> <LINK REF="REF-Scully-2008" TYPE="REFERENCE">Scully 2008</LINK>). Lichenoid dysplasia is characterised by a dysplastic surface epithelium accompanied by a band-like lymphocytic infiltrate in the subjacent lamina propria whereas histopathologic features of OLP mainly include superficial band-like infiltrate of T lymphocytes and basal cell liquefactive degeneration (<LINK REF="REF-Eisenberg-2000" TYPE="REFERENCE">Eisenberg 2000</LINK>). Current data suggest that OLP is a T-cell-mediated autoimmune disease in which auto-cytotoxic CD8 T cells trigger apoptosis of oral epithelial cells (<LINK REF="REF-Sugerman-2002" TYPE="REFERENCE">Sugerman 2002</LINK>). Interestingly, many cytokines such as TNF-alpha, IF-gamma, IL-1-alpha, IL-6, Il-8 have been implicated in the immunopathogenesis of OLP (<LINK REF="REF-Rhodus-2006" TYPE="REFERENCE">Rhodus 2006;</LINK> <LINK REF="REF-Thongprasom-2006" TYPE="REFERENCE">Thongprasom 2006;</LINK> <LINK REF="REF-Youngnak_x002d_Piboonratanakit-2009" TYPE="REFERENCE">Youngnak-Piboonratanakit 2009</LINK>)</P>
<P>In long-standing atrophic-erosive and plaque-like forms, particularly lesions of the tongue might have a higher malignant potential, but the issue of pre-malignancy remains a controversial topic and will not be addressed in this review (<LINK REF="REF-Gonzalez_x002d_Moles-2008" TYPE="REFERENCE">Gonzalez-Moles 2008</LINK>).</P>
<P>To date, a specific antigen responsible for the development of OLP remains unidentified. There is substantial fluctuation in disease activity within an individual patient and there are also variations between patients with regard to both the desire for, and response to, various treatments (<LINK REF="REF-Setterfield-2000" TYPE="REFERENCE">Setterfield 2000</LINK>). Thus reassurance, elimination of precipitating factors and control of oral hygiene are found to be useful for the initial management and can enhance healing of the symptomatic OLP lesions (<LINK REF="REF-Ramon_x002d_Fluixa-1999" TYPE="REFERENCE">Ramon-Fluixa 1999;</LINK> <LINK REF="REF-Thongprasom-2003" TYPE="REFERENCE">Thongprasom 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-06-14 10:39:20 +0100" MODIFIED_BY="[Empty name]">
<P>Various treatment regimens have been attempted to improve the lesions, and reduce the associated pain, but a cure for OLP has not yet been accomplished because of its recalcitrant nature (<LINK REF="REF-Lodi-2005b" TYPE="REFERENCE">Lodi 2005b</LINK>). Topical corticosteroids including betamethasone, clobetasol, dexamethasone, and triamcinolone; calcineurin inhibitors such as pimecrolimus, tacrolimus or cyclosporin; retinoids such as tretinoin; photochemotherapy and newer traditional medicine have been reported in the treatment of symptomatic OLP. The primary goal of treatment of symptomatic OLP is the reduction, and preferably elimination of pain associated with the lesions.</P>
</INTERVENTION>
<THEORY MODIFIED="2011-06-14 10:40:20 +0100" MODIFIED_BY="[Empty name]">
<P>OLP is a T cell-mediated autoimmune disease but its cause is unknown in most cases. OLP is likely to be the common outcome of the influence of a limited combination of extrinsic antigens, altered self-antigens or super antigens.The increased production of T helper 1 (TH1) cytokines is a key and early event in lichen planus; it is probably genetically induced (<LINK REF="REF-Carrozzo-2004" TYPE="REFERENCE">Carrozzo 2004</LINK>). Most of the treatments used for OLP aim to locally suppress T cells at large or interfere with the release of cytokine such as Tumour Necosis Factor-alpha (TNF-alpha) and Interferon-gamma (IFN-gamma) considered essential in OLP pathogenesis.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-06-14 18:07:01 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic OLP is a relatively frequent painful oral disorder that can significantly impair the quality-of-life of the patients (<LINK REF="REF-L_x00f3_pez_x002d_Jornet-2010" TYPE="REFERENCE">López-Jornet 2010</LINK>). Due to its recalcitrant nature and the lack of an apparent cause, complete cure is very difficult to achieve. Current treatments try to reduce pain and severity of lesions. There have been several traditional and some systematic reviews published (<LINK REF="REF-Cribier-1998" TYPE="REFERENCE">Cribier 1998;</LINK> <LINK REF="REF-Carrozzo-1999" TYPE="REFERENCE">Carrozzo 1999;</LINK> <LINK REF="REF-Eisen-2005" TYPE="REFERENCE">Eisen 2005;</LINK> <LINK REF="REF-Lodi-2005b" TYPE="REFERENCE">Lodi 2005b;</LINK> <LINK REF="REF-Al_x002d_Hashimi-2007" TYPE="REFERENCE">Al-Hashimi 2007;</LINK> <LINK REF="REF-Scully-2008" TYPE="REFERENCE">Scully 2008;</LINK> <LINK REF="REF-Carrozzo-2009" TYPE="REFERENCE">Carrozzo 2009</LINK>), and most of these suggest the use of topical corticosteroids or topical calcineurin inhibitors. However, a previous Cochrane review on the topic published more than 10 years ago provides only weak evidence for the superiority of any interventions over placebo for palliation of symptomatic OLP (New Reference).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-06-07 09:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>The objectives of this review are to assess the effectiveness and safety of interventions to treat symptomatic, biopsy-proven oral lichen planus.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-06-15 09:52:30 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-06-14 10:44:41 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-06-14 10:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) which compared an active treatment with placebo or with another active treatment were considered in this review. Quasi-randomised trials (where treatment assignment was by alternating sequence, date of birth, registration number or some other such non-random method) were excluded from the current update of this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-06-14 10:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>Patients satisfying the following criteria.</P>
<OL>
<LI>Having a clinical and histological diagnosis of oral lichen planus (OLP).</LI>
<LI>Having a symptomatic form of the disease.</LI>
<LI>Not concurrently taking any other treatment for OLP or treatment likely to modify their OLP (e.g. systemic steroids, antifungals or immunosuppressants).</LI>
</OL>
<P>For patients being treated for both skin and oral lichen planus, only the OLP data were extracted; if this was not possible, the study was excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-06-14 10:44:41 +0100" MODIFIED_BY="[Empty name]">
<P>Any local and/or systemic treatment was considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-01-03 13:03:08 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-01-03 13:03:08 +0000" MODIFIED_BY="[Empty name]">
<P>Pain/discomfort as assessed by patient.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-01-03 12:53:38 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical presentation of the disease in terms of extension and severity (degree of erosion, erythema and reticulation).</P>
<P>Adverse effects, including clinical candidiasis and/or other toxic and side-effects.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-06-14 10:46:59 +0100" MODIFIED_BY="[Empty name]">
<P>Non-English language papers were considered where translation was available.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-06-14 10:46:36 +0100" MODIFIED_BY="[Empty name]">
<P>For the identification of studies included or considered for this review, detailed search strategies were developed for each database searched. These were based on the search strategy developed for MEDLINE (OVID) but revised appropriately for each database. The search strategy used a combination of controlled vocabulary and free text terms and was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials (RCTs) in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the <I>Cochrane Handbook for</I> <I>Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)<I>.</I> Details of the MEDLINE search are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The search of EMBASE was linked to the Cochrane Oral Health Group filters for identifying RCTs.</P>
<P>The following electronic databases were searched:</P>
<UL>
<LI>The Cochrane Oral Health Group's Trials Register (to 26 January 2011) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>CENTRAL (<I>The Cochrane Library</I>, 2011, Issue 1) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>MEDLINE via OVID (1950 to 26 January 2011) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>EMBASE via OVID (1980 to 26 January 2011) (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-06-14 10:46:59 +0100" MODIFIED_BY="[Empty name]">
<P>The following abstracts were handsearched:</P>
<P>
<BR/>(a) abstracts of the Conference Proceedings (1995 to 2010) of the International, American, Canadian Associations, and British Society for Dental Research indexed under "Clinical Trials";<BR/>(b) abstracts of the Conference Proceedings of the British Society of Oral Medicine and European Association of Oral Medicine (1987 to 1992, 1994 to 1998; 2000 to 2010).<BR/>
</P>
<P>Bibliographies of identified publications were also checked for relevant studies, and authors were contacted to identify missing and unreported trials. The <A HREF="http://www.who.int/ictrp/en/">WHO International Trials Registry Platform</A> was searched for ongoing studies, using the term "oral lichen planus".<BR/>
<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-06-15 09:52:30 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-06-14 10:48:11 +0100" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts (when available) of all reports identified were scanned independently by two review authors. For studies appearing to meet the inclusion criteria, or for which there were insufficient data in the title and abstract to make a clear decision, the full report was obtained and was assessed independently by all review authors to establish whether the studies met the inclusion criteria or not. Disagreements were resolved by discussion. Studies rejected at this or subsequent stages were recorded in the table of excluded studies, and reasons for exclusion recorded.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-06-14 10:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>All studies meeting the inclusion criteria underwent data extraction performed by at least two review authors, using a specially designed form. The characteristics of the trial participants, interventions and outcomes for the included trials are presented in the study tables. Effects of treatment on pain and clinical presentation were measured by scales and scoring systems, often significantly different and hardly comparable. In order to maximise the availability of similar outcome we recorded also the number of patients that did not receive benefit in terms of symptoms (lack of effect on pain) and signs (lack of effect on clinical manifestations).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-15 09:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>All review authors independently assessed the risk of bias of the included trials. The full text papers were assessed independently and unblinded by all authors and any disagreement was resolved through discussion and consensus. This was conducted using the recommended approach for assessing risk of bias in studies included in Cochrane reviews (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). It is a two-part tool, addressing the six specific domains as follows.</P>
<OL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding (performance bias and detection bias).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Selective reporting (reporting bias).</LI>
<LI>Other bias.</LI>
</OL>
<P>Each domain in the tool includes one or more specific entries in a &#8216;Risk of bias&#8217; table. Within each entry, the first part of the tool describes what was reported to have happened in the study, in sufficient detail to support a judgement about the risk of bias. The second part of the tool assigns a judgement relating to the risk of bias for that entry. This is achieved by assigning a judgement of &#8216;Low risk&#8217; of bias, &#8216;High risk&#8217; of bias, or &#8216;Unclear risk&#8217; of bias.</P>
<P>After taking into account the additional information provided by the authors of the trials, studies were graded into the following categories:</P>
<P>Low risk of bias: low risk of bias for all key domains.</P>
<P>Unclear risk of bias: unclear risk of bias for one or more key domains.</P>
<P>High risk of bias: high risk of bias for one or more key domains.</P>
<P>A risk of bias table was completed for each included study (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Results are presented graphically by study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and by domain over all studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-06-14 11:45:07 +0100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes, the estimates of effects of an intervention were expressed as risk ratios (RR) together with 95% confidence intervals. For continuous outcomes, mean differences (MD) and 95% confidence intervals were used to summarise the data for each group. For paired data (split-mouth studies), generic inverse variance method was used (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-01-03 13:01:00 +0000" MODIFIED_BY="[Empty name]">
<P>The statistical unit was the patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-01-03 13:00:05 +0000" MODIFIED_BY="[Empty name]">
<P>Trialists were contacted to supply missing information and to clarify points.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-06-14 11:47:55 +0100" MODIFIED_BY="[Empty name]">
<P>The significance of any discrepancies in the estimates of the treatment effects from the different trials was assessed by means of Cochran's test for heterogeneity and the I² statistic, which describes the percentage total variation across studies that is due to heterogeneity rather than chance. Heterogeneity was considered statistically significant if the P value was less than 0.1. A rough guide to the interpretation of I² given in the Cochrane Handbook is: 0 to 40% might not be important, 30 to 60% may represent moderate heterogeneity, 50 to 90% may represent substantial heterogeneity, 75 to 100% considerable heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-07 14:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to minimise reporting biases by conducting a thorough search of multiple sources including trial registries, and efforts to identify unpublished trials and non-English language publications.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-06-14 11:48:23 +0100" MODIFIED_BY="[Empty name]">
<P>Where studies comparing similar interventions reported the same outcome measures, data were combined for meta-analysis. Risk ratios were combined for dichotomous data, and mean differences for continuous data, using fixed-effect models unless there were more than three studies being combined. Where studies reported continuous outcomes on different scales we used standardised mean difference to pool these data in meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-06-14 11:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical heterogeneity was to be assessed by examining the characteristics of patients included in the studies, however this was not necessary.</P>
<P>No subgroup analyses were planned.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-02-05 14:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>It was planned to undertake sensitivity analyses to examine the effect of the study quality assessment on the overall estimates of effect. There were too few trials to undertake this analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-06-15 12:05:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-06-14 16:23:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SEARCH_RESULTS MODIFIED="2011-06-14 11:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-eight randomised controlled trials were included in this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-06-14 13:53:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the trial settings and investigators</HEADING>
<P>Of the 28 studies included, six were conducted in Italy (<LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994;</LINK> <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>), four in Iran (<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009;</LINK> <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>), three in China (<LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002;</LINK> <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>), three in the US (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>), two in the Netherlands (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>), two in Sweden (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>), two in the UK (<LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>), one in Thailand (<LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>), one in France (<LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>), one in Germany (<LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>), one in India (<LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>), one in Spain (<LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>) and one was an Asian multicentre study (Singapore, South Korea, India, Thailand) (<LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>). The setting was a university hospital for all but four trials (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995;</LINK> <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002;</LINK> <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>).</P>
<P>Twenty-six trials had a two-arm parallel design, one a two-arm cross-over design (<LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>) and one a split-mouth design (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>). The total number of participants included in the trials was 1204, with a mean of 43 participants per study. Industry provided drugs to six trials (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), one trial received both financial support and study drug from the sponsor (<LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>), in one study one of the authors was an employee of the industry manufacturing the drug tested (<LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>), and in one study two of the authors were consultants for the industry manufacturing the drug tested (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the interventions</HEADING>
<P>In 11 trials an active intervention was compared with placebo (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008;</LINK> <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009;</LINK> <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>).</P>
<P>One study compared an active treatment with no treatment (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>), while the other 16 trials compared two active treatments.</P>
<P>Local steroids were the active intervention in 14 studies (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>). In this group six trials compared two different steroids in the two arms (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>), and two trials the same steroid with or without an antimycotic drug (<LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>). In one study all the participants received a systemic steroid (<LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>), and in another study the experimental intervention was compared with intralesional steroid (<LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>). In the 14 trials where steroids were used, clobetasol was used in six trials (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>), triamcinolone in seven trials (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009;</LINK> <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>), betamethasone in two trials (<LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>), fluocinonide in one trial (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>), fluticasone in one trial (<LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>), dexamethasone in one trial (<LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK>), and prednisolone in two trials (<LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>).</P>
<P>Local calcineurin inhibitors were employed in 10 trials. Three trials compared pimecrolimus with placebo (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>), one pimecrolimus with local triamcinolone (<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>), two tacrolimus with local steroids (<LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>), two ciclosporin with local steroids (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>) and two ciclosporin with placebo (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>).</P>
<P>Other treatments included aloe vera in two trials (<LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), Chinese traditional remedies in association with western drugs (<LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>), hyaluronic acid (<LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>), ignatia, a homeopathic medicine (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>), photochemotherapy (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>), curcuminoids as adjunctive treatment to prednisone (<LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>), purslane, a herbal medicine (<LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>), and Bacillus Calmette-Guerin polysaccharide nucleic acid (<LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the outcomes</HEADING>
<P>There were three main outcomes reported in the trials included in this review: pain, clinical signs (response) and adverse effects of treatment.</P>
<P>Pain was reported either as a continuous outcome using visual analogue scales (VAS) of different lengths (13 trials: <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>; <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>; <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>; <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>) or as a dichotomous outcome indicating the number of participants in each group who experienced a reduction in pain (seven trials: <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>; <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>; <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>; <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>).</P>
<P>Clinical signs of response to treatment was reported as area of ulceration (three studies: <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>; <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>; <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>) or as a clinical sign score (12 studies: <LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>; <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>; <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>) with a range of scoring systems used in these trials.</P>
<P>General adverse effects of treatment were reported in 16 trials (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>; <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>; <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>; <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>; <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>; <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>; <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>; <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>) and candidiasis was reported in one trial (<LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-06-14 16:23:13 +0100" MODIFIED_BY="[Empty name]">
<P>Five of the nine trials included in the previous version of this review have been excluded in this update (<LINK REF="STD-Tyldesley-1977" TYPE="STUDY">Tyldesley 1977</LINK>; <LINK REF="STD-Hersle-1982" TYPE="STUDY">Hersle 1982</LINK>; <LINK REF="STD-Giustina-1986" TYPE="STUDY">Giustina 1986</LINK>; <LINK REF="STD-Boisnic-1994" TYPE="STUDY">Boisnic 1994</LINK>; <LINK REF="STD-Harpenau-1995" TYPE="STUDY">Harpenau 1995</LINK>). <I>See</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-06-15 12:01:35 +0100" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2011-06-15 11:14:57 +0100" MODIFIED_BY="[Empty name]">
<P>The method of randomisation was considered adequate in both its components (sequence generation and allocation concealment) in 11 trials (<LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994;</LINK> <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), in six trials the sequence generation was adequate but the allocation concealment unclear (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995;</LINK> <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006;</LINK> <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009;</LINK> <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>), and in the remaining 10 trials sequence generation and allocation concealment were both unclear (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>; <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009;</LINK> <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-06-15 11:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>In 17 trials, patients and outcome assessors were both blinded (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994;</LINK> <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>: <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009;</LINK> <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), two trials reported that assessors only were blind (<LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>) and two that patients only were blinded (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>). In the other studies, patients and outcome assessors were unblinded or no clear information was provided.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-06-14 14:04:24 +0100" MODIFIED_BY="[Empty name]">
<P>In 11 trials all patients enrolled completed the study (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994;</LINK> <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002;</LINK> <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008;</LINK> <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009;</LINK> <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>), in seven trials the rate of drop-outs was less than 10% (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994;</LINK> <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002;</LINK> <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008;</LINK> <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>), in nine trials between 10 and 20% of those randomised dropped out (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995;</LINK> <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007;</LINK> <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007;</LINK> <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009;</LINK> <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), and none of the trials had more than 20% drop-outs. In one study it was not possible to establish the number of patients who did not complete the trial (<LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>). Seven trials were assessed as likely to have a high risk of bias due to missing outcome data (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>Intention to treat (ITT) analysis was performed in five trials (<LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>; <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>; <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>), was not necessary in 11, as all patients completed the study (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>; <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>; <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>, <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK>; <LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>; <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>; <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>) and was not performed in the other 12 trials.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-06-15 11:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of selective reporting was unclear in the majority of studies (15 out of 28), as information was insufficient to permit judgement. In nine studies, one or more outcomes of interest were reported incompletely (standard deviations were missing) so they could not be entered in the meta-analysis (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>; <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>; <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>; <LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>; <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>; <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>; <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>). The remaining four trials were assessed as being at low risk of selective outcome reporting bias (<LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>; <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>; <LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>; <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>)</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-06-15 12:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>In one study, two of the randomised patients (10%) were dropped from the study and replaced with another two (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>). The data from this trial shows marked imbalance at baseline.</P>
<SUBSECTION>
<HEADING LEVEL="4">Overall risk of bias</HEADING>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarise the risk of bias assessment of the studies included. None of the studies met all the risk of bias criteria and could therefore be assessed as low risk of bias. Ten studies (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>; <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>) had one or more domains assessed as unclear and are therefore considered to be at unclear risk of bias overall. The remaining 18 studies had one or more domains assessed at significant risk of bias (either no blinding, or incomplete outcome data, or selective reporting, or another risk of bias), and are therefore described as high risk of bias.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-06-15 12:05:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1) Any intervention versus placebo</HEADING>
<P>Twelve studies compared the effects of an active treatment with a placebo or no treatment. In three trials the active treatment was pimecrolimus (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>), two evaluated cyclosporine (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>), and the others tested aloe vera (<LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), photochemotherapy (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>), ignatia (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>), hyaluronic acid (<LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>), purslane (<LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>), and fluocinonide (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Mean pain score (Analysis 1.1)</HEADING>
<P>Four trials, evaluating three different interventions reported a mean pain score from a visual analogue scale: pimecrolimus (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>), cyclosporin (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>), aloe vera (<LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Two studies showed no evidence of a difference between pimecrolimus and placebo in mean pain score (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>) and there was no difference in mean pain score after treatment between aloe vera and placebo in a single study (<LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>). In a very small study of 16 patients <LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK> found a statistically significant reduction in mean pain score favouring cyclosporin. Three of these studies were at high risk of bias and <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK> was assessed as unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mean pain on feeding (Analysis 1.2)</HEADING>
<P>Only one trial in this group reported the outcome of pain during feeding and found no difference between pimecrolimus and placebo (<LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reduction in pain (Analysis 1.3)</HEADING>
<P>Four trials reported the number of patients in each group who had a reduction in pain: <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK> (pimecrolimus), <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK> (hyaluronic acid), <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK> (aloe vera), and <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK> (purslane) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was a statistically significant reduction in pain in the treatment group for both aloe vera and purslane, based on a single study for each intervention. Three of these studies are at unclear risk of bias and <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK> is at high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other pain outcomes</HEADING>
<P>
<LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK> (cyclosporin vs placebo) reported pain as one component of overall symptoms. <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK> (fluocinonide vs placebo) and <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK> (photochemotherapy vs placebo) did not report pain as an outcome and <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK> (pimecrolimus vs placebo) referred in the text to a significant reduction in meal-triggered and continuous pain in the pimecrolimus group, but reported only the P values for the difference from baseline. <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK> (ignatia vs placebo) reported a mean VAS pain score for each group but did not report any measure of variance so these data could not be used in the forest plot. <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK> is at unclear risk of bias and <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>; <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>; <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK> are at high risk of bias.</P>
<P>Overall there is weak evidence from two studies (one unclear risk of bias (<LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>) and the other high (<LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>)) that treatment with aloe vera may reduce pain associated with oral lichen planus (OLP), but data from these studies were presented in different forms and could not be combined by meta-analysis. There is weak and unreliable evidence, from two small placebo controlled trials (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>), both at high risk of bias, that cyclosporin may be effective in reducing pain and clinical signs of OLP. There is no evidence from three trials that pimecrolimus reduces pain due to OLP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical signs</HEADING>
<P>All the studies comparing an active treatment with placebo included clinical aspect among the outcomes considered. Three trials evaluated the area of ulcerated mucosa (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009;</LINK> <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>) and seven trials used clinical severity scores; either a 5-grade severity score (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>) or a 4-grade score (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009;</LINK> <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>) and <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK> calculated a weighted sums index (it was not possible to use these data in meta-analysis). Eight trials reported the dichotomous outcome of a beneficial effect on mucosa (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>; <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>). These measures of clinical effect will be described together for each intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Area of ulceration (Analysis 1.4), mean clinical score (Analysis 1.5), and clinical improvement (Analyses 1.6 and 1.7)</HEADING>
<P>
<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK> found no difference between pimecrolimus and placebo in area of ulceration in a trial at high risk of bias. <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK> (unclear risk of bias) found no difference between pimecrolimus and placebo in mean clinical score and <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK> (high risk of bias) found no difference in the outcome of clinical improvement between pimecrolimus and placebo.</P>
<P>Two studies of aloe vera reported the outcome of clinical improvement. <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK> found a statistically significant difference in clinical improvement favouring the aloe vera group but <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK> found no difference between aloe vera and placebo for this outcome. However, the pooled estimate from these two studies, one at unclear, and the other at high risk of bias, was risk ratio (RR) 1.34 (95% confidence interval (CI) 1.10 to 1.62), favouring aloe vera but with substantial heterogeneity (Chi² = 10.18, df = 1, P = 0.001, I² = 90%). The pooled estimate for mean clinical score also showed a benefit favouring aloe vera.</P>
<P>A small study with 16 participants (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>) found a statistically significant reduction in mean clinical score in the cyclosporin group compared to placebo, and <LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK> found that clinical improvement was greater in the cyclosporin group. We sought clarification of the data from the trial by <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>, but due the passage of time since this study was published we were unable to obtain clarification. However there is some indication that the cyclosporin group had a reduction in clinical signs compared to placebo. Both of these studies are at high risk of bias and they have a combined total of 36 participants, so these results should be interpreted with caution.</P>
<P>Another single study with 40 participants, assessed at unclear risk of bias (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993</LINK>), found a statistically significant reduction in clinical sign scores, and a greater rate of clinical improvement in the fluocinonide group compared to placebo.</P>
<P>Hyaluronic acid showed a statistically significant reduction in area of ulceration compared to placebo in a single study assessed as being at high risk of bias (<LINK REF="STD-Nolan-2009" TYPE="STUDY">Nolan 2009</LINK>).</P>
<P>In a split-mouth study at high risk of bias, <LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK> found a benefit in favour of photochemotherapy with methoxsalen (0.6 mg/kg) and UVA irradiation compared to placebo in a small group of 18 participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects (Analysis 1.8)</HEADING>
<P>Six studies comparing an active treatment with placebo included data on adverse effects among the outcomes considered (<LINK REF="STD-Voute-1993" TYPE="STUDY">Voute 1993;</LINK> <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005;</LINK> <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007;</LINK> <LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008;</LINK> <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008;</LINK> <LINK REF="STD-Agha_x002d_Hosseini-2010" TYPE="STUDY">Agha-Hosseini 2010</LINK>). The split-mouth design did not allow a comparison of adverse effects (<LINK REF="STD-Lundquist-1995" TYPE="STUDY">Lundquist 1995</LINK>), while <LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK> reported it was not possible to distinguish between the incidence of adverse effects in the two groups. When present, adverse effects were more common in the treatment group compared with placebo group, but the difference was not statistically significant in any of the studies (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2) Steroids versus calcineurin inhibitors</HEADING>
<P>Five studies compared the effects of a topical steroid (clobetasol or triamcinolone) with a topical calcineurin inhibitor (cyclosporin, tacrolimus or pimecrolimus). Each of the studies compared a different pair of drugs: clobetasol and cyclosporine (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>), clobetasol and tacrolimus (<LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>), triamcinolone and pimecrolimus (<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>), triamcinolone and tacrolimus (<LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>), triamcinolone and cyclosporine (<LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>). Data are presented in forest plots but no meta-analysis was possible.</P>
<SUBSECTION>
<HEADING LEVEL="4">Pain (Analyses 2.1 and 2.2)</HEADING>
<P>Pain was included among the outcomes considered by all but one study comparing a steroid with a calcineurin inhibitor (<LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>).</P>
<P>Two trials reported VAS values for pain at the end of the study (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006;</LINK> <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>), one reported results from a 0 to 3 scale at the end of the treatment (<LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK>) and one reported VAS pain changes from baseline (<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>).</P>
<P>Topical cyclosporine was compared with topical clobetasol (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>) or triamcinolone (<LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK>) in studies at unclear and high risk of bias respectively. Neither study showed any difference between these interventions for the outcome of pain. Pimecrolimus was compared with triamcinolone in a study at unclear risk of bias (<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>) and found no difference in the change in pain scores from baseline (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK> showed a statistically significant difference in mean pain score favouring tacrolimus compared to those treated with clobetasol (standardised mean difference (SMD) 1.72, 95% CI 0.89 to 2.55) in a total of 32 patients in a study at unclear risk of bias.</P>
<P>Only one study reported the number of patients who had reduced pain as a result of treatment (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>): no difference was shown between cyclosporine and clobetasol (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Overall there is no evidence of a difference between steroids and calcineurin inhibitors with regard to pain associated with OLP, from this series of single studies evaluating different drugs from each group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical signs: area of ulceration (Analysis 2.3), mean clinical score (Analysis 2.4) and clinical improvement (Analysis 2.5)</HEADING>
<P>All the studies comparing steroid with a calcineurin inhibitor included clinical aspect among the outcomes considered, either area of ulceration, mean clinical scores in each group or numbers of participants showing clinical improvement per group. Results from the five studies are described below together with the estimates of adverse effects of treatments (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</P>
<P>
<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK> compared topical clobetasol with topical cyclosporin in a study assessed as being at unclear risk of bias, and <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK> compared topical triamcinolone with cyclosporin in a study at high risk of bias. There was a statistically significant reduction in the mean area of ulceration in the triamcinolone group in <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK> (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) but neither study found a difference in the rate of clinical improvement between the steroids and the calcineurin inhibitor (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). <LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK> found that reduced clinical score favoured the steroid group (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) and reported a greater frequency of adverse effects in this group (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), but the difference in adverse effects was not statistically significant. <LINK REF="STD-Yoke-2006" TYPE="STUDY">Yoke 2006</LINK> found a statistically significantly greater frequency of adverse effects in the cyclosporin group (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>
<LINK REF="STD-Laeijendecker-2006" TYPE="STUDY">Laeijendecker 2006</LINK>, in a small study at high risk of bias, compared triamcinolone with tacrolimus and found a benefit favouring tacrolimus as measured by both mean clinical score and numbers of patients improved (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), and no statistically significant difference in the frequency of adverse effects in each group (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>
<LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>, in a trial at unclear risk of bias, found no difference between triamcinolone and pimecrolimus in either mean clinical score at the end of treatment (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), or in the frequency of adverse effects (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>However <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK> found that mean clinical score at the end of treatment favoured tacrolimus compared to clobetasol (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), and there were no adverse effects reported in either group in this trial at unclear risk of bias.</P>
<P>From these studies of 'head to head' comparisons there is no consistent evidence of a class effect of topical steroids compared to calcineurin inhibitors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects (Analysis 2.6)</HEADING>
<P>All five studies which compared a topical steroid with a topical calcineurin inhibitor reported adverse effects. One study <LINK REF="STD-Corrocher-2008" TYPE="STUDY">Corrocher 2008</LINK> reported an increased burning sensation in the tacrolimus group that reduced as the lesions healed. Only one study, comparing clobetasol and cyclosporine, showed higher incidence of adverse effects among patients treated with steroid (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>), while all the others showed higher incidence of adverse effects in the calcineurin inhibitor group. The most frequently reported adverse effects were transient burning or stinging associated with application and some patients also reported dyspepsia, skin rashes, local swelling, and gastrointestinal upsets.</P>
<P>One study, conducted in Italy between 1999 and 2002, also compared the costs of cyclosporine (&#8364;1.82 per day) and clobetasol (&#8364;0.35 per day) (<LINK REF="STD-Conrotto-2006" TYPE="STUDY">Conrotto 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3) Steroids versus steroids</HEADING>
<P>Six studies compared two different steroids or different formulation/doses of the same steroid. The comparisons were; clobetasol ointment with triamcinolone ointment (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>), fluticasone spray with betamethasone mouthrinse (<LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>), clobetasol (0.025%) in microspheres with clobetasol ointment (0.025%) (<LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>), systemic betamethasone with triamcinolone oral paste (<LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>), two different concentrations of clobetasol ointment (0.05% versus 0.025%) (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>), and mucoadhesive prednisolone tablet with triamcinolone acetonide paste (<LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>). Two of these studies (<LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>) were assessed at unclear risk of bias and four were at high risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="4">Pain (Analyses 3.1 and 3.2)</HEADING>
<P>Pain was included among the outcomes considered by all six studies comparing topical steroids, but only two studies reported pain scores in a form suitable for inclusion in forest plots.</P>
<P>There was no difference between low dose clobetasol ointment (0.025%) and higher dose clobetasol ointment (0.05%) in one study (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>). However, in the study comparing two different vehicles for applying clobetasol 0.025%, the group who used the microsphere formulation reported lower pain scores (<LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>). Both these trials were at unclear risk of bias and, because there was only a single study in each comparison, results should be interpreted with caution (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>
<LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK> did not report data on pain assessment specifically, but stated in the text that "no statistical (significant) difference in the symptomatic improvement was found between the two groups" taking oral betamethasone and triamcinolone oral paste. Two studies reported point estimates for pain, but no estimates of variance were included so these data could not be used in meta-analysis (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>; <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>). <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK> used a cross-over design to compare fluticasone and betamethasone sprays but the data reported were not presented or analysed as paired data and so could not be used in this review.</P>
<P>From these trials there is no evidence that any specific steroid therapy is more or less effective at reducing pain compared to another type or dose of steroid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical signs (Analysis 3.3) and clinical improvement (Analysis 3.4)</HEADING>
<P>All the studies comparing steroids included a clinical aspect among the outcomes reported.</P>
<P>Continuous clinical score data were available from two studies comparing steroids. <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK> and <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK> used the Thongprasom scoring system to evaluate clinical signs (<LINK REF="REF-Thongprasom-1992" TYPE="REFERENCE">Thongprasom 1992</LINK>), and neither study found a difference between the steroids compared. <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK> used a scoring system based on erosion but presented only means without an estimate of variance for each group, so these data could not be used in the systematic review.</P>
<P>It was not possible to analyse data from <LINK REF="STD-Hegarty-2002" TYPE="STUDY">Hegarty 2002</LINK>, comparing fluticasone propionate spray and betamethasone, as these data were not presented in a paired form as would be expected in a cross-over study.</P>
<P>Effect on clinical signs was measured as number of patients who had a clinical improvement as a result of treatment and was reported in five trials (<LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK>; <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK>; <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Ghabanchi-2009" TYPE="STUDY">Ghabanchi 2009</LINK>). All evaluated different comparisons but none of the steroidal treatments showed significant superiority (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects (Analysis 3.5)</HEADING>
<P>Data on adverse effects were available from four studies. In one study no adverse effects were noted in either group (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>), in <LINK REF="STD-Campisi-2004" TYPE="STUDY">Campisi 2004</LINK> the two formulations of clobetasol caused adverse effects with similar frequency, in <LINK REF="STD-Malhotra-2008" TYPE="STUDY">Malhotra 2008</LINK> oral betamethasone caused significantly more adverse effects than triamcinolone oral paste, and in <LINK REF="STD-Rodstrom-1994" TYPE="STUDY">Rodstrom 1994</LINK> adverse effects were recorded in three patients only, all from the clobetasol group (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4) Antifungals as adjunctive treatment to steroids</HEADING>
<P>Two studies investigated the effect of antifungals as adjunctive treatment to steroids, with regard to improving OLP and/or preventing candidosis secondary to local immunosuppression (<LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003;</LINK> <LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>). One compared dexamethasone with and without nystatin (<LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK>, unclear risk of bias) and the other clobetasol gel with and without miconazole gel (<LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>, high risk of bias).</P>
<SUBSECTION>
<HEADING LEVEL="4">Pain (Analysis 4.1)</HEADING>
<P>One study included pain among the outcomes considered (<LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>). There was no difference in pain, measured as a continuous variable in the two groups in this study (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical signs (Analyses 4.2 and 4.3)</HEADING>
<P>Both studies comparing steroids with and without antifungal included a clinical aspect among the outcomes reported.</P>
<P>
<LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK> found no difference in the percentage of oral mucosa affected by ulceration between the adjunctive antifungal and steroid-only groups (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), and <LINK REF="STD-Wei-2003" TYPE="STUDY">Wei 2003</LINK> found no difference in the number of patients in each group reporting a clinical improvement (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Candidosis (Analysis 4.4)</HEADING>
<P>As expected the incidence of candidosis was eliminated in the group receiving antifungal treatment in the study that reported this outcome (<LINK REF="STD-Lodi-2007" TYPE="STUDY">Lodi 2007</LINK>) (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5) Other treatment comparisons</HEADING>
<P>One study was designed to assess the effect of adjunctive treatment with curcuminoids (compounds found to have anti-inflammatory effects and used in Ayurvedic medicine) in patients also receiving treatment with oral prednisone (<LINK REF="STD-Chainani_x002d_Wu-2007" TYPE="STUDY">Chainani-Wu 2007</LINK>). This study planned to recruit 100 participants but recruitment stopped after a planned interim analysis failed to show a significant difference between the adjunctive curcuminoid and placebo groups. There was no difference in pain reduction in the 28 patients assessed at the first interim analysis (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>One study compared local injections with Bacillus Calmette-Guerin polysaccharide nucleic acid (BCG-PSN) with triamcinolone acetonide (<LINK REF="STD-Xiong-2009" TYPE="STUDY">Xiong 2009</LINK>). Neither pain (measured by VAS) or signs (measured as area of ulceration), or clinical improvement showed a statistically significant difference between the two treatments (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). Incidence of adverse effects was similar in the two groups (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
<P>One study compared a 3-stage treatment integrating Western and Chinese medicine, with a 2-stage Western medicine approach. Western-Chinese included topical application of herbal pulvis, herbal decoction together with oral steroid (prednisone), oral antihistamine (chlorphenamine), and Vitamin C using gradually decreasing doses, followed by herbal decoction alone. The comparison group received prednisone, chlorphenamine and Vitamin C in fixed dose, followed by a phase of gradually decreasing dosage (<LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>). The outcome was assessed using a clinical score and this trial, assessed as being at unclear risk of bias, found a benefit favouring the integrated Chinese and Western medicine that just attained statistical significance (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). All three studies in this group were at high risk of bias.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-06-15 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-06-15 11:25:22 +0100" MODIFIED_BY="[Empty name]">
<P>In the present update of the systematic review on oral lichen planus (OLP) treatment, we included 28 randomised controlled trials (RCTs) compared to the nine trials which were included in the previous version published in 1999 (<LINK REF="REF-Chan-1999" TYPE="REFERENCE">Chan 1999</LINK>). Five of the nine trials included in the previous version have been excluded in this update. Pain is the primary outcome of this review because it is the indication for treatment of OLP, and therefore we indicate as effective, only those treatments which significantly reduce pain.</P>
<UL>
<LI>There were 12 studies which compared a range of eight different active treatments with placebo. There is no evidence from the three trials of pimecrolimus that this treatment is better than placebo in reducing pain from OLP. There is weak evidence from two trials (<LINK REF="STD-Choonhakarn-2008" TYPE="STUDY">Choonhakarn 2008</LINK>; <LINK REF="STD-Salazar_x002d_Sanchez-2010" TYPE="STUDY">Salazar-Sanchez 2010</LINK>), at unclear and high risk of bias respectively, that aloe vera may be associated with a reduction in pain but it was not possible to pool the pain data from these trials. There is weak and unreliable evidence, from two small placebo controlled trials (<LINK REF="STD-Eisen-1990" TYPE="STUDY">Eisen 1990</LINK>; <LINK REF="STD-Gaeta-1994" TYPE="STUDY">Gaeta 1994</LINK>), both at high risk of bias, that cyclosporin may be effective in reducing pain and clinical signs of OLP.</LI>
<LI>There were five trials that compared steroids with calcineurin inhibitors, each evaluating a different pair of interventions. There is no evidence from these trials that there is a difference between treatment with steroids compared to any of the calcineurin inhibitors evaluated (cyclosporin, tacrolimus or pimecrolimus) with regard to reducing pain associated with OLP.</LI>
<LI>Six trials compared different steroid treatments. From these trials there is no evidence that any specific steroid therapy is more or less effective at reducing pain compared to another type or dose of steroid.</LI>
<LI>There is insufficient evidence to determine whether adjunctive antifungal therapy, curcuminoids or combinations of traditional Chinese medicine with Western medicine, or BCG-PSN are effective treatments for OLP pain.</LI>
</UL>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-06-15 09:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>In this review, there were different interventions, comparisons, dosages, concentrations, vehicles and time of application used in the trials, together with a range of outcome measures, making it difficult to evaluate the treatments, and meta-analyse data. When information in the trial reports was inadequate or unclear, trial authors were contacted and asked to provide missing information. Although steroid treatment is considered by many to be 'first line' treatment for OLP (<LINK REF="REF-Normile-2008" TYPE="REFERENCE">Normile 2008</LINK>), we did not identify any placebo-controlled trials of steroids for treating symptomatic OLP. Thus we found no RCT evidence to support the effectiveness of steroid treatment for OLP.  </P>
<P>A major issue is whether a placebo-controlled RCT is ethically acceptable for symptomatic patients with OLP. In fact, on one hand, placebo-controlled trials of local steroids are missing, and on the other hand, local steroids are universally recognised as first line treatment, and for this reason perhaps steroids (and not placebo) should be the ideal control group (<LINK REF="REF-Normile-2008" TYPE="REFERENCE">Normile 2008</LINK>). However, from the trials included in this review it is not clear which steroid formulation, concentration or dosage regimen represents 'standard of care'.</P>
<P>Because of small sample size in many trials, it is likely that there was a lack of power to detect significant differences between treatments if indeed such a difference existed. Although there has been an increase in number of studies, most of the negative remarks made by <LINK REF="REF-Chan-1999" TYPE="REFERENCE">Chan 1999</LINK> may be repeated here. After more than 10 years there is still a lack of strong evidence supporting the effectiveness of any specific palliative treatment for symptomatic OLP.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-06-15 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of trials was generally poor; no studies met all the risk of bias criteria and none were assessed as low risk of bias. The majority of trials (18 trials, 64%) were assessed as being at high risk of bias, and the remainder were unclear, mostly due to missing information. Use of the CONSORT guidelines for reporting studies is still the exception rather than the rule.</P>
<P>Another important issue is lack of uniformity in the outcomes employed to assess treatment efficacy. This is a major obstacle in comparing and pooling together results of different studies. This problem is common to other inflammatory disorders frequently affecting the oral cavity such as pemphigus vulgaris and mucous membrane pemphigoid (<LINK REF="REF-Bagan-2005" TYPE="REFERENCE">Bagan 2005;</LINK> <LINK REF="REF-Black-2005" TYPE="REFERENCE">Black 2005</LINK>). Indeed a review of clinical trials studying pemphigus has revealed a total of 116 outcome measures described in 96 articles over the past 25 years (<LINK REF="REF-Martin-2008" TYPE="REFERENCE">Martin 2008</LINK>). However, OLP is relatively common and the lack of well-designed studies is quite certainly not related to the prevalence of the disease. However, given the very variable clinical course and diverse features of OLP, a definition of clinically meaningful treatment effectiveness may be problematic in this disease. Therefore, there needs to be generalised agreement as to the clinical types of OLP, and ideally OLP clinical trials should include at least a measure of improvement of symptoms, specifically pain, as one of the primary outcomes.</P>
<P>Pain is the primary outcome of this review, as it is most often the reason for patients seeking treatment.  Measuring pain as an outcome in clinical trials of treatments for OLP is important, but it is also difficult due to the fluctuating nature of OLP pain and variations between patients. In addition pain scores may be influenced by the timing of the pain evaluation; assessments between meals, while eating or while performing oral care may all give rise to different pain scores. </P>
<P>Moreover, future RCTs should measure symptoms and clinical features by means of the same standardised outcome, which should be reliable (i.e. giving the same value each time it is used), sensible (i.e. able to catch even minimal clinically important changes), accurate and feasible (relatively easy to use) and it should be validated (<LINK REF="REF-Bastuji_x002d_Garin-2009" TYPE="REFERENCE">Bastuji-Garin 2009</LINK>). Improvement of clinical signs of OLP was assessed using a clinical criteria score (<LINK REF="REF-Thongprasom-1992" TYPE="REFERENCE">Thongprasom 1992</LINK>) in only 32% of studies in this review. In the remaining studies a variety of assessments were used. The lack of a widely accepted system for scoring the clinical severity of OLP makes it difficult to compare the effectiveness of drugs within and between individual patients, and in drug trials between different institutions. Therefore, clinical assessment criteria should be established and accepted by clinicians and trialists before further RCTs are undertaken. Likewise VAS pain scales should be administered in a standardised and well validated system, so that pain symptoms can be compared between patients and between interventions.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-02-10 11:41:12 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of any source of bias due to the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-06-15 09:46:47 +0100" MODIFIED_BY="[Empty name]">
<P>One of the more significant findings of the present review is that there is no evidence that pimecrolimus is effective in OLP treatment. This is surprising when considering that all the four RCTs published (<LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>; <LINK REF="STD-Gorouhi-2007" TYPE="STUDY">Gorouhi 2007</LINK>; <LINK REF="STD-Passeron-2007" TYPE="STUDY">Passeron 2007</LINK>; <LINK REF="STD-Volz-2008" TYPE="STUDY">Volz 2008</LINK>) reported that pimecrolimus is an effective treatment. This can perhaps be explained by the analysis method employed (before-after comparison instead of comparison between groups).</P>
<P>On the other hand, whereas this review did not find strong evidence that calcineurin inhibitors are effective, the US Food and Drugs Administration has issued a &#8220;Black Box&#8221; warning attached to the use of tacrolimus and pimecrolimus because of a theoretical increased risk of malignancy (squamous cell carcinoma (SCC) and lymphoma) in patients using topical tacrolimus/pimecrolimus for cutaneous psoriasis. Moreover, two recent case reports suggested that the topical use of tacrolimus 0.1% in patients with OLP may promote the development of a SCC of the tongue (<LINK REF="REF-Becker-2006" TYPE="REFERENCE">Becker 2006;</LINK> <LINK REF="REF-Mattsson-2010" TYPE="REFERENCE">Mattsson 2010</LINK>).</P>
<P>As already mentioned, many more studies have been included in the present review, compared with previous version (<LINK REF="REF-Chan-1999" TYPE="REFERENCE">Chan 1999</LINK>) and other evidence-based reviews (<LINK REF="REF-Cribier-1998" TYPE="REFERENCE">Cribier 1998</LINK>). </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-06-15 11:26:32 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-06-15 11:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>There are no trials comparing topical steroids with placebo and these may now be considered unethical. There are many trials comparing different steroids with different alternative treatments, with little duplication. There is no evidence that one steroid treatment is better or worse than another. There is weak evidence to suggest that aloe vera may reduce pain and clinical signs of oral lichen planus (OLP), compared to placebo. There is weak and unreliable evidence that cyclosporin may reduce pain and clinical signs of OLP. There is no evidence that pimecrolimus is more effective than placebo. Although there are 28 trials included in this systematic review the wide range of interventions compared means there is insufficient evidence to support any specific treatment as being superior.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-06-15 09:48:41 +0100" MODIFIED_BY="[Empty name]">
<P>There is a stringent need to standardise the methodology of OLP intervention trials mainly in relation to the assessment used. Future trials should measure the outcomes of symptoms and clinical assessment using standardised measures. It has been difficult to compare the effectiveness of drugs within and between individual patients, and different institutions. Moreover, long-term follow-up, adverse effects of treatment and cost-effectiveness should be included in the trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-06-14 15:54:26 +0100" MODIFIED_BY="[Empty name]">
<P>Philip Riley and Anne Littlewood (Cochrane Oral Health Group (COHG), Manchester) for managing the editorial process and for searching trials respectively. We would like to thank the COHG for funding support. University of Milan, Italy and Chulalongkorn University, Bangkok, Thailand are acknowledged for encouragement and support for this review.</P>
<P>We also thank Professor Helen Worthington, Co-ordinating Editor of the COHG, for organising and supporting our group meeting in Milan, Italy, 2009.</P>
<P>Professor Shi Zongdao, Dr Wang Ping and Dr Xie Huixu of the West China College of Stomatology, Sichuan University, Chengdu, China for the Chinese translation. Dr Mark Schiefter for suggestions on the background of this update review. Associate Professor Mookhda Siritapetawee and Assistant Professor Paiboon Techalertpaisarn for technical assistance. All of the referees for their invaluable comments.</P>
<P>This update review has been developed from Chan ESY, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. <I>Cochrane Database of Systematic Reviews</I> 1999, Issue 2. Art. No.: CD001168. DOI: 10.1002/14651858.CD001168.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-06-14 16:09:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Professor Kobkan Thongprasom</HEADING>
<UL>
<LI>Searched electronic databases.</LI>
</UL>
<UL>
<LI>Searched bibliographies of identified publications.</LI>
</UL>
<UL>
<LI>Handsearched abstracts of the Conference Proceedings of the International, American, Canadian Associations, and British Society for Dental Research.</LI>
</UL>
<UL>
<LI>Contacted authors of the relevant studies.</LI>
</UL>
<UL>
<LI>Screened full articles of selected trials to confirm eligibility, assess quality and extract data.</LI>
</UL>
<UL>
<LI>Assessed the methodological quality of selected trials.</LI>
</UL>
<UL>
<LI>Wrote and edited the text of the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Marco Carrozzo</HEADING>
<UL>
<LI>Searched electronic databases.</LI>
</UL>
<UL>
<LI>Searched bibliographies of identified publications.</LI>
</UL>
<UL>
<LI>Handsearched abstracts of the Conference Proceedings of the International, American, Canadian Associations, and British Society for Dental Research.</LI>
</UL>
<UL>
<LI>Contacted authors of the relevant studies.</LI>
</UL>
<UL>
<LI>Assessed quality of the extracted data.</LI>
</UL>
<UL>
<LI>Assessed the methodological quality of selected trials.</LI>
</UL>
<UL>
<LI>Wrote and edited the text of the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Susan Furness</HEADING>
<UL>
<LI>Assessed the risk of bias of included studies.</LI>
</UL>
<UL>
<LI>Extracted the data from the included studies and entered it into Revman.</LI>
</UL>
<UL>
<LI>Contributed to the statistical analysis.</LI>
</UL>
<UL>
<LI>Wrote and edited the text of the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Giovanni Lodi</HEADING>
<UL>
<LI>Searched electronic databases.  </LI>
</UL>
<UL>
<LI>Searched bibliographies of identified publications.</LI>
</UL>
<UL>
<LI>Handsearched abstracts of the Conference Proceedings of the International, American, Canadian Associations, and British Society for Dental Research.</LI>
</UL>
<UL>
<LI>Contacted authors of the relevant studies.</LI>
</UL>
<UL>
<LI>Screened full articles of selected trials to confirm eligibility, assess quality and extract data.</LI>
</UL>
<UL>
<LI>Assessed the methodological quality of selected trials.</LI>
</UL>
<UL>
<LI>Performed the statistical analysis.</LI>
</UL>
<UL>
<LI>Wrote and edited the text of the review.</LI>
</UL>
<P> </P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-06-14 16:24:15 +0100" MODIFIED_BY="[Empty name]">
<P>Two additional criteria have been added for trials eligible for inclusion in this review.</P>
<OL>
<LI>All participants in the included trials must be symptomatic.</LI>
<LI>All participants in the included trials must have clinical diagnosis of OLP confirmed by biopsy.</LI>
</OL>
<P>One of the previous inclusion criteria has been deleted</P>
<OL>
<LI>Quasi-randomised trials will not be considered eligible for this review.</LI>
</OL>
<P>
<B> </B>These changes resulted in five trials previously included in this review, being excluded from the 2011 update.</P>
<P>Boisnic 1994, Giustina 1986 and Hersle 1982 are now excluded from this review because participants in these trials did not have symptomatic OLP. Tyldesley 1977 was excluded because the participants in this trial did not have the diagnosis of OLP confirmed by biopsy, and Harpenau 1995 was excluded because this trial was quasi-randomised.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-06-15 08:57:45 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-06-14 17:44:00 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-06-14 17:31:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agha_x002d_Hosseini-2010" MODIFIED="2011-06-14 17:16:06 +0100" MODIFIED_BY="[Empty name]" NAME="Agha-Hosseini 2010" YEAR="2009">
<REFERENCE MODIFIED="2011-06-14 17:16:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agha-Hosseini F, Borhan-Mojabi K, Monsef-Esfahani HR, Mirzaii-Dizgah I, Etemad-Moghadam S, Karagah A</AU>
<TI>Efficacy of purslane in the treatment of oral lichen planus</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>2</NO>
<PG>240-4</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:16:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campisi-2004" MODIFIED="2011-06-14 17:16:25 +0100" MODIFIED_BY="[Empty name]" NAME="Campisi 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-06-14 17:16:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campisi G, Giandalia G, De Caro V, Di Liberto C, Arico P, Giannola LI</AU>
<TI>A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2004</YR>
<VL>150</VL>
<NO>5</NO>
<PG>984-90</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:16:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbone-2009" MODIFIED="2011-06-14 17:16:58 +0100" MODIFIED_BY="[Empty name]" NAME="Carbone 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-14 17:16:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carbone M, Arduino PG, Carrozzo M, Caiazzo G, Broccoletti R, Conrotto D, et al</AU>
<TI>Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>2</NO>
<PG>227-33</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:16:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chainani_x002d_Wu-2007" MODIFIED="2011-06-14 17:17:14 +0100" MODIFIED_BY="[Empty name]" NAME="Chainani-Wu 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-14 17:17:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, et al</AU>
<TI>A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>7-8</NO>
<PG>437-46</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:17:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choonhakarn-2008" MODIFIED="2011-06-14 17:17:52 +0100" MODIFIED_BY="[Empty name]" NAME="Choonhakarn 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:17:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P</AU>
<TI>The efficacy of aloe vera gel in the treatment of oral lichen planus: a randomized controlled trial</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2008</YR>
<VL>158</VL>
<NO>3</NO>
<PG>573-7</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:17:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Conrotto-2006" MODIFIED="2011-06-14 17:18:37 +0100" MODIFIED_BY="[Empty name]" NAME="Conrotto 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-14 17:18:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, Pentenero M, et al</AU>
<TI>Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>154</VL>
<NO>1</NO>
<PG>139-45</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:18:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrocher-2008" MODIFIED="2011-06-14 17:18:52 +0100" MODIFIED_BY="[Empty name]" NAME="Corrocher 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:18:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Corrocher G, Di Lorenzo G, Martinelli N, Mansueto P, Biasi D, Nocini PF, et al</AU>
<TI>Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>3</NO>
<PG>244-9</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:18:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisen-1990" MODIFIED="2011-06-14 17:19:11 +0100" MODIFIED_BY="[Empty name]" NAME="Eisen 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-06-14 17:19:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eisen D, Ellis CN, Duell EA, Griffiths CE, Voorhees JJ</AU>
<TI>Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<NO>5</NO>
<PG>290-4</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:19:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gaeta-1994" MODIFIED="2011-06-14 17:19:59 +0100" MODIFIED_BY="[Empty name]" NAME="Gaeta 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-06-14 17:19:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaeta GM, Serpico R, Femiano F, La Rotonda MI, Cappello B, Gombos F</AU>
<TI>Cyclosporin bioadhesive gel in the topical treatment of erosive oral lichen planus</TI>
<SO>International Journal of Immunopathology and Pharmacology</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>125-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghabanchi-2009" MODIFIED="2011-06-14 17:20:16 +0100" MODIFIED_BY="[Empty name]" NAME="Ghabanchi 2009" YEAR="2009. Date of Publication: 2009">
<REFERENCE MODIFIED="2011-06-14 17:20:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(Ghabanchi) Department of Oral Medicine, Faculty of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of. (Bahri Najafi) Department of Pharmacology, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of. (Haghnegahdar) Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of&lt;/p&gt;" NOTES_MODIFIED="2011-06-14 17:20:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ghabanchi J, Bahri Najafi R, Haghnegahdar S</AU>
<TI>Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone table versus triamcinolone acetonide paste</TI>
<SO>Iranian Red Crescent Medical Journal</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>2</NO>
<PG>155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorouhi-2007" MODIFIED="2011-06-14 17:20:39 +0100" MODIFIED_BY="[Empty name]" NAME="Gorouhi 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-14 17:20:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gorouhi F, Solhpour A, Beitollahi JM, Afshar S, Davari P, Hashemi P, et al</AU>
<TI>Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>5</NO>
<PG>806-13</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:20:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hegarty-2002" MODIFIED="2011-06-14 17:20:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hegarty 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-14 17:20:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hegarty AM, Hodgson TA, Lewsey JD, Porter SR</AU>
<TI>Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>2</NO>
<PG>271-9</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:20:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laeijendecker-2006" MODIFIED="2011-06-14 17:21:04 +0100" MODIFIED_BY="[Empty name]" NAME="Laeijendecker 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-14 17:21:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laeijendecker R, Tank B, Dekker SK, Neumann HA</AU>
<TI>A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>3</NO>
<PG>227-9</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:20:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lodi-2007" MODIFIED="2011-06-14 17:21:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lodi 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-14 17:21:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lodi G, Tarozzi M, Sardella A, Demarosi F, Canegallo L, Di Benedetto D, et al</AU>
<TI>Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>156</VL>
<NO>6</NO>
<PG>1336-41</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:21:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundquist-1995" MODIFIED="2011-06-14 17:22:14 +0100" MODIFIED_BY="[Empty name]" NAME="Lundquist 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-06-14 17:22:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lundquist G, Forsgren H, Gajecki M, Emtestam L</AU>
<TI>Photochemotherapy of oral lichen planus. A controlled study</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1995</YR>
<VL>79</VL>
<NO>5</NO>
<PG>554-8</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:21:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malhotra-2008" MODIFIED="2011-06-14 17:24:16 +0100" MODIFIED_BY="[Empty name]" NAME="Malhotra 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:23:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khaitan BK, Malhotra A, Sharma VK, Sethuraman G</AU>
<TI>Efficacy and safety of betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide oral paste in oral lichen planus: a randomized comparative study (Abstract FC03.11)</TI>
<SO>Journal of the of the European Academy of Dermatology and Venereology</SO>
<YR>2005</YR>
<VL>19 Suppl 2</VL>
<PG>12-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-14 17:24:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malhotra AK, Khaitan BK, Sethuraman G, Sharma VK</AU>
<TI>Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: A randomized comparative study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>4</NO>
<PG>596-602</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:24:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mousavi-2009" MODIFIED="2011-06-14 17:24:46 +0100" MODIFIED_BY="[Empty name]" NAME="Mousavi 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-14 17:24:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mousavi F, Sherafati S, Mojaver YN</AU>
<TI>Ignatia in the treatment of oral lichen planus</TI>
<SO>Homeopathy</SO>
<YR>2009</YR>
<VL>98</VL>
<NO>1</NO>
<PG>40-4</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:24:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolan-2009" MODIFIED="2011-06-14 17:25:22 +0100" MODIFIED_BY="[Empty name]" NAME="Nolan 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-14 17:25:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nolan A, Badminton J, Maguire J, Seymour RA</AU>
<TI>The efficacy of topical hyaluronic acid in the management of oral lichen planus</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>3</NO>
<PG>299-303</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:25:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passeron-2007" MODIFIED="2011-06-14 17:25:40 +0100" MODIFIED_BY="[Empty name]" NAME="Passeron 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-14 17:25:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Passeron T, Lacour JP, Fontas E, Ortonne JP</AU>
<TI>Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood</TI>
<SO>Archives of Dermatology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>4</NO>
<PG>472-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:25:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rodstrom-1994" MODIFIED="2011-06-14 17:27:09 +0100" MODIFIED_BY="[Empty name]" NAME="Rodstrom 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-06-14 17:27:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodstrom PO, Hakeberg M, Jontell M, Nordin P</AU>
<TI>Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in Orabase: a double-blind clinical trial</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-14 17:26:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodstrom PO, et al</AU>
<TI>Treatment of oral lichen planus by topical application of Clobetasol Propionate (Dermovat) in Orabase (IADR Abstract 1123)</TI>
<SO>Journal of Dental Research</SO>
<YR>1992</YR>
<VL>72</VL>
<PG>656</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Salazar_x002d_Sanchez-2010" MODIFIED="2011-06-14 17:27:47 +0100" MODIFIED_BY="[Empty name]" NAME="Salazar-Sanchez 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-14 17:27:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salazar-Sánchez N, López-Jornet P, Camacho-Alonso F, Sánchez-Siles M</AU>
<TI>Efficacy of topical Aloe vera in patients with oral lichen planus: a randomized double-blind study</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>10</NO>
<PG>735-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swift-2005" MODIFIED="2011-06-14 17:28:03 +0100" MODIFIED_BY="[Empty name]" NAME="Swift 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-14 17:28:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC</AU>
<TI>The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus</TI>
<SO>Journal of Periodontology</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>4</NO>
<PG>627-35</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:27:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volz-2008" MODIFIED="2011-06-14 17:28:16 +0100" MODIFIED_BY="[Empty name]" NAME="Volz 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:28:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volz T, Caroli U, Ludtke H, Brautigam M, Kohler-Spath H, Rocken M, et al</AU>
<TI>Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2008</YR>
<VL>159</VL>
<NO>4</NO>
<PG>936-41</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:28:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voute-1993" MODIFIED="2011-06-14 17:28:48 +0100" MODIFIED_BY="[Empty name]" NAME="Voute 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-06-14 17:28:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Voute AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I</AU>
<TI>Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1993</YR>
<VL>75</VL>
<NO>2</NO>
<PG>181-5</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:28:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2003" MODIFIED="2011-06-14 17:29:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wei 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-06-14 17:29:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wei X, Li BQ, Zhou XD, Chen QM</AU>
<TI>Clinical effect of mycostatin paste plus dexamethasone paste in treatment of patients with OLP</TI>
<SO>Journal of Clinical Stomatology</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>9</NO>
<PG>568-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiong-2009" MODIFIED="2011-06-14 17:29:37 +0100" MODIFIED_BY="[Empty name]" NAME="Xiong 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-14 17:29:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Xiong C, Li Q, Lin M, Li X, Meng W, Wu Y, et al</AU>
<TI>The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>7</NO>
<PG>551-8</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:29:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2002" MODIFIED="2011-06-14 17:30:19 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-14 17:30:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Xu YZ, Geng Y, Liu YX, Fuan YQ, Li J</AU>
<TI>Clinical study on three-step treatment of oral lichen planus by integrated traditional and western medicine</TI>
<SO>Journal of Modern Stomatology</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>4</NO>
<PG>344-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoke-2006" MODIFIED="2011-06-14 17:31:01 +0100" MODIFIED_BY="[Empty name]" NAME="Yoke 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-14 17:31:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yoke PC, Tin GB, Kim MJ, Rajaseharan A, Ahmed S, Thongprasom K, et al</AU>
<TI>A randomized controlled trial to compare steroid with cyclosporine for the topical treatment of oral lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2006</YR>
<VL>102</VL>
<NO>1</NO>
<PG>47-55</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:30:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-06-14 17:41:56 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boisnic-1994" MODIFIED="2011-06-14 17:31:46 +0100" MODIFIED_BY="[Empty name]" NAME="Boisnic 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-06-14 17:31:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H</AU>
<TI>Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation</TI>
<SO>Annales de Dermatologie et de Venereologie</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>6-7</NO>
<PG>459-63</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:31:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouloc-2000" MODIFIED="2011-06-14 17:32:01 +0100" MODIFIED_BY="[Empty name]" NAME="Bouloc 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-06-14 17:32:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bouloc A, Revuz J, Bagot M, Wechsler J, Natta P</AU>
<TI>KH 1060 for the treatment of lichen planus: a multicenter, randomized, double-blind, vehicle-controlled study</TI>
<SO>Archives of dermatology</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>10</NO>
<PG>1272</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:32:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buajeeb-1997" MODIFIED="2011-06-14 17:32:35 +0100" MODIFIED_BY="[Empty name]" NAME="Buajeeb 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-06-14 17:32:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buajeeb W, Kraivaphan P, Pobrurksa C</AU>
<TI>Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1997</YR>
<VL>83</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:32:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buajeeb-2000" MODIFIED="2011-06-14 17:33:00 +0100" MODIFIED_BY="[Empty name]" NAME="Buajeeb 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-06-14 17:33:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buajeeb W, Pobrurksa C, Kraivaphan P</AU>
<TI>Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2000</YR>
<VL>89</VL>
<NO>1</NO>
<PG>42-5</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:33:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2008" MODIFIED="2011-06-14 17:33:43 +0100" MODIFIED_BY="[Empty name]" NAME="Chang 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:33:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang ALS, Badger J, Rehmus W, Kimball AB</AU>
<TI>Alefacept for erosive lichen planus: a case series</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>4</NO>
<PG>339-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cilurzo-2010" MODIFIED="2011-06-14 17:34:54 +0100" MODIFIED_BY="[Empty name]" NAME="Cilurzo 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-14 17:34:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cilurzo F, Gennari CG, Selmin F, Epstein JB, Gaeta GM, Colella G, et al</AU>
<TI>A new mucoadhesive dosage form for the management of oral lichen planus: formulation study and clinical study</TI>
<SO>European Journal of Pharmaceutics and Biopharmaceutics</SO>
<YR>2010</YR>
<VL>76</VL>
<NO>3</NO>
<PG>437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delavarian-2010" MODIFIED="2011-06-14 17:36:09 +0100" MODIFIED_BY="[Empty name]" NAME="Delavarian 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-14 17:36:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(Delavarian, Javadzade-Bolouri, Dalirsani) Mashhad University of Medical Sciences, Department of Oral Medicine, Mashhad Dental School, Mashhad, Iran, Islamic Republic of. School, Mashhad, Iran, Islamic Republic of&lt;/p&gt;" NOTES_MODIFIED="2011-06-14 17:36:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Delavarian Z, Javadzadeh-Bolouri A, Dalirsani Z, Arshadi HR, Toofani-Asl H</AU>
<TI>The evaluation of psychiatric drug therapy on oral lichen planus patients with psychiatric disorders</TI>
<SO>Medicina Oral, Patologia Oral y Cirugia Bucal</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>2</NO>
<PG>e322-7</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:35:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giustina-1986" MODIFIED="2011-06-14 17:36:33 +0100" MODIFIED_BY="[Empty name]" NAME="Giustina 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-06-14 17:36:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giustina TA, Stewart JC, Ellis CN, Regezi JA, Annesley T, Woo TY, et al</AU>
<TI>Topical application of isotretinoin gel improves oral lichen planus. A double-blind study</TI>
<SO>Archives of Dermatology</SO>
<YR>1986</YR>
<VL>122</VL>
<NO>5</NO>
<PG>534-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:36:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glade-1998" MODIFIED="2011-06-14 17:36:54 +0100" MODIFIED_BY="[Empty name]" NAME="Glade 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-06-14 17:36:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glade CP, Van Der Vleuten CJ, van Erp PE, De Jong EM, van de Kerkhof PC</AU>
<TI>The epidermis of chronic idiopathic lichen planus during topical treatment with the vitamin D3 analogue KH 1060</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>1</NO>
<PG>14-8</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:36:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-1978" MODIFIED="2011-06-14 17:37:21 +0100" MODIFIED_BY="[Empty name]" NAME="Greenspan 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-06-14 17:37:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan JS, Yeoman CM, Harding SM</AU>
<TI>Oral lichen planus. A double-blind comparison of treatment with betamethasone valerate aerosol and pellets</TI>
<SO>British Dental Journal</SO>
<YR>1978</YR>
<VL>144</VL>
<NO>3</NO>
<PG>83-4</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:37:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunther-1973" MODIFIED="2011-06-14 17:38:56 +0100" MODIFIED_BY="[Empty name]" NAME="Gunther 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-06-14 17:38:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunther S</AU>
<TI>The therapeutic value of retinoic acid (vitamin A acid) in lichen planus of the oral mucous membrane</TI>
<SO>Dermatologica</SO>
<YR>1973</YR>
<VL>147</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:38:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hantash-2007" MODIFIED="2011-06-14 17:39:13 +0100" MODIFIED_BY="[Empty name]" NAME="Hantash 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-14 17:39:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hantash BM, Kanzler MH</AU>
<TI>The efficacy of tetracycline antibiotics for treatment of lichen planus: an open-label clinical trial</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>156</VL>
<NO>4</NO>
<PG>758-60</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:39:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harpenau-1995" MODIFIED="2011-06-14 16:21:52 +0100" MODIFIED_BY="[Empty name]" NAME="Harpenau 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-06-14 16:21:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harpenau LA, Plemons JM, Rees TD</AU>
<TI>Effectiveness of a low dose of cyclosporine in the management of patients with oral erosive lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1995</YR>
<VL>80</VL>
<NO>2</NO>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hersle-1982" MODIFIED="2011-06-14 17:39:49 +0100" MODIFIED_BY="[Empty name]" NAME="Hersle 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-06-14 17:39:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hersle K, Mobacken H, Sloberg K, Thilander H</AU>
<TI>Severe oral lichen planus: treatment with an aromatic retinoid (etretinate)</TI>
<SO>The British Journal of Dermatology</SO>
<YR>1982</YR>
<VL>106</VL>
<NO>1</NO>
<PG>77-80</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:39:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellett-1990" MODIFIED="2011-06-14 17:40:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kellett 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-06-14 17:40:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kellett JK, Ead RD</AU>
<TI>Treatment of lichen planus with a short course of oral prednisolone</TI>
<SO>The British Journal of Dermatology</SO>
<YR>1990</YR>
<VL>123</VL>
<NO>4</NO>
<PG>550-1</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:40:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurberg-1991" MODIFIED="2011-06-14 17:40:19 +0100" MODIFIED_BY="[Empty name]" NAME="Laurberg 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-06-14 17:40:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurberg G, Geiger JM, Hjorth N, Holm P, Hou-Jensen K, Jacobsen KU, et al</AU>
<TI>Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>3</NO>
<PG>434-7</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:40:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCaughey-2010" MODIFIED="2011-06-14 17:41:02 +0100" MODIFIED_BY="[Empty name]" NAME="McCaughey 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-14 17:41:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCaughey C, Machan M, Bennett R, Zone J, Hull C</AU>
<TI>Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2010</YR>
<VL>Epub ahead of print</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radfar-2008" MODIFIED="2011-06-14 17:41:40 +0100" MODIFIED_BY="[Empty name]" NAME="Radfar 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-14 17:41:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radfar L, Wild RC, Suresh L</AU>
<TI>A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>2</NO>
<PG>187-93</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:41:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyldesley-1977" MODIFIED="2011-06-14 17:41:56 +0100" MODIFIED_BY="[Empty name]" NAME="Tyldesley 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-06-14 17:41:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyldesley WR, Harding SM</AU>
<TI>Betamethasone valerate aerosol in the treatment of oral lichen planus</TI>
<SO>The British Journal of Dermatology</SO>
<YR>1977</YR>
<VL>96</VL>
<NO>6</NO>
<PG>659-62</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:41:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-06-14 17:44:00 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Jajarm-2011" MODIFIED="2011-06-14 17:42:54 +0100" MODIFIED_BY="[Empty name]" NAME="Jajarm 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-06-14 17:42:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jajarm HH, Falaki F, Mahdavi O</AU>
<TI>A comparative pilot study of low intensity laser versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus</TI>
<SO>Photomedicine and Laser Surgery</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>6</NO>
<PG>421-5</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:42:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Javadzadeh-2008" MODIFIED="2011-04-21 09:22:33 +0100" MODIFIED_BY="[Empty name]" NAME="Javadzadeh 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-04-21 09:22:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(Javadzadeh, Delavarian, Shirazian) Department of Oral Medicine and Dental Research Center, Faculty of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of. (Vatanpour) Department of Toxicology, School of Pharmacy, Shaheed Beheshti University (M. C.), Tehran, Iran, Islamic Republic of. (Momajed) Helal Health and Science Co., Tehran, Iran, Islamic Republic of. (Esmaeily) Department of Public Medical Health, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of. (Vatanpour) Department of Endodontics, Faculty of Dentistry, Islamic Azad University, Tehran, Iran, Islamic Republic of&lt;/p&gt;" NOTES_MODIFIED="2011-04-21 09:22:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Javadzadeh A, Vatanpour H, Delavarian Z, Momajed A, Esmaeily H, Vatanpour M, et al</AU>
<TI>Efficacy of clobetasol, ketoconazole and amitriptyline mouthwash on oral lichen planus</TI>
<SO>Iranian Journal of Pharmaceutical Research</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>3</NO>
<PG>171-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-01-20 16:03:36 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2011-06-14 17:43:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-14 17:43:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin LM, Qi XM</AU>
<TI>Comparative observation on the effects of Radix tripterygium hypoglaucum tablet and Tripterygium glycosides tablet in treating erosive oral lichen planus</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>149-50</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:43:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2010" MODIFIED="2011-06-14 17:44:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-06-14 17:44:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Zhou G, Zeng H, Xiong CR, Lin M, Zhou HM</AU>
<TI>A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2010</YR>
<VL>110</VL>
<NO>2</NO>
<PG>188-95</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:44:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-07-09 15:47:58 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-15 08:57:45 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-14 18:07:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Al_x002d_Hashimi-2007" MODIFIED="2011-06-14 17:44:55 +0100" MODIFIED_BY="[Empty name]" NAME="Al-Hashimi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al</AU>
<TI>Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2007</YR>
<VL>103 Suppl 1</VL>
<PG>S25.e1-12</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:44:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bagan-2005" MODIFIED="2011-06-14 17:45:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bagan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bagan J, Lo Muzio L, Scully C</AU>
<TI>Mucosal disease series. Number III. Mucous membrane pemphigoid</TI>
<SO>Oral Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>197-218</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:45:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bastuji_x002d_Garin-2009" MODIFIED="2011-06-14 17:45:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bastuji-Garin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bastuji-Garin S, Sbidian E</AU>
<TI>How to validate outcome instruments for pemphigus</TI>
<SO>The Journal of Investigative Dermatology</SO>
<YR>2009</YR>
<VL>129</VL>
<NO>10</NO>
<PG>2328-30</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:45:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Becker-2006" MODIFIED="2011-04-20 12:18:13 +0100" MODIFIED_BY="[Empty name]" NAME="Becker 2006" TYPE="JOURNAL_ARTICLE">
<AU>Becker JC, Houben R, Vetter CS, Bröcker EB</AU>
<TI>The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report</TI>
<SO>BMC Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2005" MODIFIED="2011-06-14 17:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Black 2005" TYPE="JOURNAL_ARTICLE">
<AU>Black M, Mignogna MD, Scully C</AU>
<TI>Number II. Pemphigus vulgaris</TI>
<SO>Oral Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>119-30</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:46:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carrozzo-1999" MODIFIED="2011-06-14 17:46:30 +0100" MODIFIED_BY="[Empty name]" NAME="Carrozzo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Carrozzo M, Gandolfo S</AU>
<TI>The management of oral lichen planus</TI>
<SO>Oral Diseases</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>196-205</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:46:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carrozzo-2004" MODIFIED="2011-06-14 17:47:17 +0100" MODIFIED_BY="[Empty name]" NAME="Carrozzo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, et al</AU>
<TI>Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus</TI>
<SO>The Journal of Investigative Dermatology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>1</NO>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carrozzo-2009" MODIFIED="2011-06-14 17:47:53 +0100" MODIFIED_BY="[Empty name]" NAME="Carrozzo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Carrozzo M, Thorpe R</AU>
<TI>Oral lichen planus: a review</TI>
<SO>Minerva Stomatologica</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>10</NO>
<PG>519-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cribier-1998" MODIFIED="2011-06-14 17:52:39 +0100" MODIFIED_BY="[Empty name]" NAME="Cribier 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cribier B, Frances C, Chosidow O</AU>
<TI>Treatment of lichen planus. An evidence-based medicine analysis of efficacy</TI>
<SO>Archives of Dermatology</SO>
<YR>1998</YR>
<VL>134</VL>
<NO>12</NO>
<PG>1521-30</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:52:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eisen-2002" MODIFIED="2011-06-14 17:53:11 +0100" MODIFIED_BY="[Empty name]" NAME="Eisen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Eisen D</AU>
<TI>The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>2</NO>
<PG>207-14</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:53:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eisen-2005" MODIFIED="2011-06-14 17:53:26 +0100" MODIFIED_BY="[Empty name]" NAME="Eisen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K</AU>
<TI>Number V Oral lichen planus: clinical features and management</TI>
<SO>Oral Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>6</NO>
<PG>338-49</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:53:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eisenberg-2000" MODIFIED="2011-06-14 17:53:59 +0100" MODIFIED_BY="[Empty name]" NAME="Eisenberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg E</AU>
<TI>Oral lichen planus: a benign lesion</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>11</NO>
<PG>1278-85</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:53:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Escudier-2007" MODIFIED="2011-06-14 17:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Escudier 2007" TYPE="JOURNAL_ARTICLE">
<AU>Escudier M, Ahmed N, Shirlaw P, Setterfield J, Tappuni A, Black MM, et al</AU>
<TI>A scoring system for mucosal disease severity with special reference to oral lichen planus</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>4</NO>
<PG>765-70</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:54:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez_x002d_Moles-2008" MODIFIED="2011-06-14 17:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez-Moles 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Moles MA, Scully C, Gil-Montoya JA</AU>
<TI>Oral lichen planus: controversies surrounding malignant transformation</TI>
<SO>Oral Diseases</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>3</NO>
<PG>229-43</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:54:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-06-14 17:56:40 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].</SO>
<YR>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lodi-2005a" MODIFIED="2011-06-14 17:57:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lodi 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K</AU>
<TI>Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>1</NO>
<PG>40-51</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:56:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lodi-2005b" MODIFIED="2011-06-14 17:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lodi 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K</AU>
<TI>Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>2</NO>
<PG>164-78</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:58:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Jornet-2010" MODIFIED="2011-06-14 17:58:39 +0100" MODIFIED_BY="[Empty name]" NAME="López-Jornet 2010" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F</AU>
<TI>Quality of life in patients with oral lichen planus</TI>
<SO>Journal of Evaluation in Clinical Practice</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>1</NO>
<PG>111-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-2008" MODIFIED="2011-06-14 17:58:56 +0100" MODIFIED_BY="[Empty name]" NAME="Martin 2008" TYPE="OTHER">
<AU>Martin LK, Murrell DF</AU>
<TI>Treatment of pemphigus: the need for more evidence</TI>
<SO>Archives of Dermatology</SO>
<YR>2008</YR>
<VL>144</VL>
<NO>1</NO>
<PG>100-1</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:58:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Mattsson-2010" MODIFIED="2011-06-14 17:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Mattsson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mattsson U, Magnusson B, Jontell M</AU>
<TI>Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2010</YR>
<VL>110</VL>
<NO>1</NO>
<PG>e19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCartan-2008" MODIFIED="2011-06-14 17:59:48 +0100" MODIFIED_BY="[Empty name]" NAME="McCartan 2008" TYPE="JOURNAL_ARTICLE">
<AU>McCartan BE, Healy CM</AU>
<TI>The reported prevalence of oral lichen planus: a review and critique</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>8</NO>
<PG>447-53</PG>
<IDENTIFIERS MODIFIED="2011-06-14 17:59:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Normile-2008" MODIFIED="2011-06-14 18:00:10 +0100" MODIFIED_BY="[Empty name]" NAME="Normile 2008" TYPE="OTHER">
<AU>Normile D</AU>
<TI>Ethics. Clinical trials guidelines at odds with U.S. policy</TI>
<SO>Science (New York, N.Y.)</SO>
<YR>2008</YR>
<VL>322</VL>
<NO>5901</NO>
<PG>516</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:00:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ramon_x002d_Fluixa-1999" MODIFIED="2011-06-14 18:00:26 +0100" MODIFIED_BY="[Empty name]" NAME="Ramon-Fluixa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ramon-Fluixa C, Bagan-Sebastian J, Milian-Masanet M, Scully C</AU>
<TI>Periodontal status in patients with oral lichen planus: a study of 90 cases</TI>
<SO>Oral Diseases</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>303-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:00:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rhodus-2006" MODIFIED="2011-06-14 18:00:34 +0100" MODIFIED_BY="[Empty name]" NAME="Rhodus 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F</AU>
<TI>Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone</TI>
<SO>Oral Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>112-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:00:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Scully-2008" MODIFIED="2011-06-14 18:01:58 +0100" MODIFIED_BY="[Empty name]" NAME="Scully 2008" TYPE="JOURNAL_ARTICLE">
<AU>Scully C, Carrozzo M</AU>
<TI>Oral mucosal disease: Lichen planus</TI>
<SO>The British Journal of Oral &amp; Maxillofacial Surgery</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>1</NO>
<PG>15-21</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:01:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Setterfield-2000" MODIFIED="2011-06-14 18:02:24 +0100" MODIFIED_BY="[Empty name]" NAME="Setterfield 2000" TYPE="JOURNAL_ARTICLE">
<AU>Setterfield JF, Black MM, Challacombe SJ</AU>
<TI>The management of oral lichen planus</TI>
<SO>Clinical and Experimantal Dermatology</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>3</NO>
<PG>176-82</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:02:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sugerman-2002" MODIFIED="2011-06-14 18:03:43 +0100" MODIFIED_BY="[Empty name]" NAME="Sugerman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al</AU>
<TI>The pathogenesis of oral lichen planus</TI>
<SO>Critical Reviews in Oral Biology and Medicine</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>4</NO>
<PG>350-65</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:03:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thongprasom-1992" MODIFIED="2011-06-14 18:04:26 +0100" MODIFIED_BY="[Empty name]" NAME="Thongprasom 1992" TYPE="JOURNAL_ARTICLE">
<AU>Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W</AU>
<TI>Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>10</NO>
<PG>456-8</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:04:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thongprasom-2003" MODIFIED="2011-06-14 18:04:43 +0100" MODIFIED_BY="[Empty name]" NAME="Thongprasom 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C</AU>
<TI>Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>6</NO>
<PG>315-22</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:04:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thongprasom-2006" MODIFIED="2011-06-14 18:04:57 +0100" MODIFIED_BY="[Empty name]" NAME="Thongprasom 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M</AU>
<TI>Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>3</NO>
<PG>161-6</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:04:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thornhill-2001" MODIFIED="2011-06-14 18:05:36 +0100" MODIFIED_BY="[Empty name]" NAME="Thornhill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thornhill MH</AU>
<TI>Immune mechanisms in oral lichen planus</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>2001</YR>
<VL>59</VL>
<NO>3</NO>
<PG>174-7</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:05:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Youngnak_x002d_Piboonratanakit-2009" MODIFIED="2011-06-14 18:06:04 +0100" MODIFIED_BY="[Empty name]" NAME="Youngnak-Piboonratanakit 2009" TYPE="JOURNAL_ARTICLE">
<AU>Youngnak-Piboonratanakit P, Dhanuthai K, Thongprasom K, Luckprom P, Sarideechaigul W, Luangjarmekorn L, et al</AU>
<TI>Expression of IFN-gamma before and after treatment of oral lichen planus with 0.1% fluocinolone acetonide in orabase</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>9</NO>
<PG>689-94</PG>
<IDENTIFIERS MODIFIED="2011-06-14 18:05:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-06-14 18:07:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chan-1999" MODIFIED="2011-06-14 18:07:01 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 1999" TYPE="COCHRANE_REVIEW">
<AU>Chan ESY, Thornhill M, Zakrzewska JJM</AU>
<TI>Interventions for treating oral lichen planus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001168. DOI: 10.1002/14651858.CD001168"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-06-15 08:57:45 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-06-15 11:18:29 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-06-15 11:18:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-06-14 16:28:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<CHAR_METHODS MODIFIED="2011-06-14 16:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Iran</P>
<P>Number of centres: 2 (Tehran, Qazvin)</P>
<P>Recruitment period: April 2006-May 2008</P>
<P>Funding source: the present study was supported by a grant (no. NCT00746772) from Qazvin University of Medical Sciences</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:28:48 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histopathological diagnosis of OLP based on &#8216;a modified definition of the WHO, signing an informed consent, availability for monthly appointments up to 6 months and the presence of symptoms such as burning or pain in and around the lesions.</P>
<P>Exclusion criteria: participants demonstrating histological signs of dysplasia, lichenoid drug reactions, drug consumption in the past month, pregnancy or any kind of localised or systemic disease, especially renal problems were excluded from the study sample. Patients receiving immunosuppressive or immunomodulatory treatments or any kind of systemic or local drugs were either eliminated or asked to discontinue their treatment for a minimum of 1 month before entering the investigation.</P>
<P>Group A: randomised 20; analysed 20</P>
<P>Group B: randomised 17; analysed 17</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 10:43:53 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: purslane 235 mg extract, one pill per day for 3 months</P>
<P>Group B: placebo, one pill per day for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 10:44:15 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:28:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Campisi-2004">
<CHAR_METHODS MODIFIED="2011-06-14 16:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical diagnosis of symptomatic atrophic/erosive OLP; histological confirmation of OLP; naive status (no previous treatment for OLP in the last 6 months); willingness (written informed consent) and ability to complete the trial.</P>
<P>Exclusion criteria: histological presence of dysplasia; use of drugs associated with lichenoid reactions; contemporary skin and/or genital lesions, pregnancy, immuno-dysfunction and haematological disease.</P>
<P>Group A: randomised 20; analysed 18</P>
<P>Group B: randomised 30; analysed 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:53:54 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: clobetasol propionate in microspheres 0.025%, two applications daily for the first month and one application daily for the second month</P>
<P>Group B: clobetasol propionate 0.025% in a dispersion of a lipophilic ointment in a hydrophilic phase, two applications daily for the first month and one application daily for the second month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 10:46:42 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-15 14:24:19 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:30:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carbone-2009">
<CHAR_METHODS MODIFIED="2010-11-10 10:53:59 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: 2005-2006</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histological diagnosis of OLP on the basis of WHO criteria: hyperkeratosis of the superficial epithelial layers, vacuolar degeneration of the germinative layer of the epithelium and band-like sub-epithelial lymphocytic inflammatory infiltrate; presence of painful and atrophic-erosive oral lesions, at the same time with reticular ones; ability to complete the present clinical trial.</P>
<P>Exclusion criteria: presence of histological signs of dysplasia; use of lichenoid reaction inducing drugs; presence of amalgam fillings close to lesions; therapy for OLP in the 6 months prior to the study; skin, genital or other extra-oral lesions; pregnant or breastfeeding women; proved or suspected hypersensitivity caused by the tested chemicals.</P>
<P>Group A: randomised 18; analysed 15</P>
<P>Group B: randomised 17; analysed 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-05 16:05:17 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: clobetasol 0.025% in HEC, two applications daily for 2 months</P>
<P>Group B: clobetasol 0.05% in HEC, two applications daily for 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 13:17:24 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom), relapses, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-15 14:24:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:32:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<CHAR_METHODS MODIFIED="2011-06-14 16:31:09 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: USA</P>
<P>Number of centres: 1</P>
<P>Recruitment period: February 2003-August 2004 (then stopped for futility following an interim analysis)</P>
<P>Funding source: Mount Zion Health Found, through UCSF</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: Over age 21 years, with a current presentation of atrophic or erosive OLP, and a symptom score for OLP between 3 and 8 at enrolment. All patients had been diagnosed by clinical as well as histopathological examination of oral lesions.</P>
<P>Exclusion criteria: pregnancy, lactation, a medical contraindication to prednisone or fluconazole, patients on long-term corticosteroid therapy, current use of anticoagulants or antiplatelet agents, current orthodontic treatment, and history of gastric ulcers, duodenal ulcers, gallstones or liver disease.</P>
<P>Group A: randomised 17; analysed 17 (ITT analysis)</P>
<P>Group B: randomised 16; analysed 16 (ITT analysis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 10:50:40 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: 60 mg prednisone and 2000 mg of curcuminoids per day (in two divided doses), for 7 weeks</P>
<P>Group B: 60 mg prednisone and placebo per day (in two divided doses), for 7 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 15:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (modified oral mucositis index), change in symptoms scale, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-14 16:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>Among patients who completed the study, all patients in the placebo group had &gt; 85% compliance, and 14 had &gt; 95% compliance (range 87.7-100%); in the curcuminoids group, all but one had &gt; 95% compliance (range 64.2-100%).</P>
<P>Comment: after enrolling 33 subjects the study was halted for futility following an interim analysis. Estimated post hoc power to detect a difference was 7%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:33:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choonhakarn-2008">
<CHAR_METHODS MODIFIED="2010-11-10 10:49:17 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Thailand</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: Grant from Khon Kaen University</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histopathological diagnosis of OLP; age at least 18 years.</P>
<P>Exclusion criteria: pregnant women; lesions in contact with dental amalgam; the use of drugs possibly causing a lichenoid reaction; any treatment for OLP or immunosuppressive drugs for pre-existing diseases within the 4 weeks prior to the study; and a history of hypersensitivity to AV.</P>
<P>Group A: randomised 27; analysed 27</P>
<P>Group B: randomised 27; analysed 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-20 15:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: Aloe vera gel (70% Aloe vera mucilage), twice a day for 8 weeks                       </P>
<P>Group B: Placebo, (composition not described) twice a day for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical response (4-grade scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 13:50:16 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:33:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conrotto-2006">
<CHAR_METHODS MODIFIED="2010-11-03 10:54:35 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: 1999-2002</P>
<P>Funding source: industry provided drugs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:33:56 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histological OLP; painful lesions.</P>
<P>Exclusion criteria: presence of histological signs of dysplasia; use of lichenoid reaction-inducing drugs; presence of amalgam fillings close to lesions; therapy for OLP in the 6 months prior to the study; skin, genital or other extraoral lesions; pregnant or breastfeeding women.</P>
<P>Group A: randomised 20; analysed 19</P>
<P>Group B: randomised 20; analysed 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 10:55:29 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: 0.025% Clobetasol propionate in hydroxyethyl cellulose, twice a day for 2 months</P>
<P>Group B: 1.5 % Ciclosporine in hydroxyethyl cellulose, twice a day for 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom), adverse effects, cost</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 10:56:01 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:35:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corrocher-2008">
<CHAR_METHODS MODIFIED="2010-11-03 10:57:08 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:34:53 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients aged &gt; 18 years; moderate to severe OLP; clinical and histological diagnosis.</P>
<P>Exclusion criteria: presence of skin and/or genital lesions, histopathologic signs of dysplasia, treatment with drugs that may induce lichenoid reactions, previous treatment with systemic corticosteroids, immunosuppressant therapy, topical glucocorticoids or tacrolimus within the previous 8 weeks, chronic liver disease, immune system dysfunction, haematological disease, pregnancy, and lactation.</P>
<P>Group A: randomised 16; analysed 16</P>
<P>Group B: randomised 16; analysed 16</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: tacrolimus 0.1% ointment 2 ml four times daily for 4 weeks</P>
<P>Group B: clobetasol 0.05% ointment 2 ml four times daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:35:05 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (4-grade scale), clinical score (4-grade scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:38:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eisen-1990">
<CHAR_METHODS MODIFIED="2011-06-14 16:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: USA</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: two of the authors were consultants for the industry manufacturing the drug tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:37:25 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histological diagnosis, symptomatic OLP.</P>
<P>Exclusion criteria: cutaneous LP.</P>
<P>Group A: randomised 8; analysed 8</P>
<P>Group B: randomised 8; analysed 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: cyclosporin rinse (100 mg/ml) rinsing for 5 minutes 3 times daily for 8 weeks</P>
<P>Group B: placebo rinsing for 5 minutes 3 times daily for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (4-grade scale), erosion and erythema (4-grade scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:38:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaeta-1994">
<CHAR_METHODS MODIFIED="2010-11-10 10:51:04 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histological diagnosis, symptomatic OLP, lesions involving more than 50% of the oral cavity, normal liver function, normal creatinemia, resistance to local therapies (steroids, tretinoine).</P>
<P>Exclusion criteria: concomitant therapies with nephrotoxic effects.</P>
<P>Group A: randomised 10; analysed 10</P>
<P>Group B: randomised 10; analysed 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-12 10:17:09 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: 16 mg of cyclosporine in bioadhesive gel 3 times daily for 10 weeks</P>
<P>Group B: bioadhesive gel times daily for 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-13 16:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Complete healing, reduction in clinical signs of OLP<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-20 14:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
<BR/>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:39:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghabanchi-2009">
<CHAR_METHODS MODIFIED="2011-06-14 16:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Iran</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: Shiraz University of Medical Sciences</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: not specified.</P>
<P>Exclusion criteria: not specified.</P>
<P>Group A: randomised 9; analysed 9</P>
<P>Group B: randomised 11; analysed 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:39:46 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: mucoadhesive prednisolone tablet (5 mg), 2 times a day, for 2 weeks</P>
<P>Group B: triamcinolone acetonide paste (0.1%), 3 times a day, for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:39:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical score (5-grade score)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:40:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorouhi-2007">
<CHAR_METHODS MODIFIED="2010-11-03 11:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Iran</P>
<P>Number of centres: 1</P>
<P>Recruitment period: May 2005-January 2006</P>
<P>Funding source: industry provided drugs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with histopathologically proven OLP older than 8 years (18?).</P>
<P>Exclusion criteria: malignant or viral involvement in the mouth; had received topical therapy for OLP in the last 2 weeks or systemic therapy in the last 4 weeks; used azathioprine, cyclosporine, psoralen plus ultraviolet (UV) A, UVA, or UVB in the last month; or had a history of allergy to either immunomodulators or corticosteroids.</P>
<P>Group A: randomised 20; analysed 18</P>
<P>Group B: randomised 20; analysed 17</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 11:45:51 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: pimecrolimus 1% cream, 4 times daily, for 2 months</P>
<P>Group B: triamcinolone acetonide 0.1% paste, 4 times daily, for 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-07 11:27:05 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom), quality of life (OHIP), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 16:05:28 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:42:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hegarty-2002">
<CHAR_METHODS MODIFIED="2011-06-14 16:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT 2-arm cross-over</P>
<P>Conducted in: UK</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:41:48 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: symptomatic erosive or ulcerative OLP, had not previously used fluticasone or betamethasone, and were generally healthy.</P>
<P>Exclusion criteria: unclear.</P>
<P>Group A: randomised 22; analysed 19</P>
<P>Group B: randomised 22; analysed 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:42:01 +0100" MODIFIED_BY="[Empty name]">
<P>Fluticasone spray (50 &#956;g), 2 puffs applied to lesions 4 times daily, for 6 weeks and betamethasone sodium phosphate 500 &#956;g (0.5 mg in 10 ml of water), 3 minutes mouthrinse 4 times daily, for 6 weeks.</P>
<P>Group A: sequence fluticasone and betamethasone</P>
<P>Group B: sequence betamethasone and fluticasone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:42:24 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (mm² of lesions), quality of life (OHIP, OHQoL), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-14 16:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>All 5 patients that left the study (3 in group A and 2 in group B) did so during fluticasone treatment because of adverse effects</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:43:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laeijendecker-2006">
<CHAR_METHODS MODIFIED="2010-11-10 10:51:57 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Netherlands</P>
<P>Number of centres: 1</P>
<P>Recruitment period: between 2001-2004</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: caucasian patients with a confirmed diagnosis of symptomatic OLP based on clinical and histopathological features.</P>
<P>Exclusion criteria: age younger than 18 years; histopathological examination with atypical or lichenoid dysplastic features; asymptomatic oral lesions and specific treatment within 4 weeks prior to the study.</P>
<P>Group A: randomised 20; analysed 20</P>
<P>Group B: randomised 20; analysed 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 11:55:01 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: tacrolimus 0.1% ointment, 4 times daily, for 6 weeks</P>
<P>Group B: triamcinolone acetonide 0.1% in hypromellose 20% ointment, 4 times daily, for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:43:58 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical score (4-grade score), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 17:55:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:44:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lodi-2007">
<CHAR_METHODS MODIFIED="2010-11-03 11:56:26 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Italy</P>
<P>Number of centres: 1</P>
<P>Recruitment period: May 2002-January 2003                 </P>
<P>Funding source: University of Milan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:44:37 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histological diagnosis of OLP; symptomatic form of the disease; and age over 18 years.</P>
<P>Exclusion criteria: previous treatment for OLP; systemic or local treatment with antifungal or corticosteroids in the 6 months prior to the study; hypersensitivity to clobetasol propionate or miconazole; or uncontrolled diabetes or hypertension, systemic conditions that could hamper participation and compliance with the study.</P>
<P>Group A: randomised 18; analysed 15</P>
<P>Group B: randomised 17; analysed 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-07 12:28:16 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: clobetasol propionate gel 0.05% (A) and miconazole 2% gel (B); A twice daily and B once daily, 6 weeks</P>
<P>Group B: clobetasol propionate gel 0.05% (A) and placebo gel (B); A twice daily and B once daily, 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 11:57:30 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (% of mucosa affected), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:46:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundquist-1995">
<CHAR_METHODS MODIFIED="2011-06-14 16:45:41 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT, split-mouth </P>
<P>Conducted in: Sweden</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:46:32 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: not specified.</P>
<P>Exclusion criteria: evidence or an anamnestic report of renal or hepatic disease, sensitivities to light, or eye diseases or those who were pregnant.</P>
<P>Number of patients randomised: 18</P>
<P>Number of patients analysed: 16</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-08 15:44:59 +0000" MODIFIED_BY="[Empty name]">
<P>Side A: treatments with methoxsalen (0.6 mg/kg) and UVA irradiation (0.75 J/cm2, increased by 0.25 J/cm2 every other session).</P>
<P>Side B: no treatment (mucosa protected by aluminium foil).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:46:40 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical score (3-grade scale), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-20 14:00:57 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:47:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malhotra-2008">
<CHAR_METHODS MODIFIED="2010-11-03 12:00:05 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: India</P>
<P>Number of centres: 1</P>
<P>Recruitment period: January 2003-March 2004</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients included had either exclusive oral involvement or predominant oral involvement with few skin lesions, and had not received any treatment in the previous 4 weeks.</P>
<P>Exclusion criteria: children (age\15 years); elderly patients (age &gt; 65 years); pregnant and lactating women; and patients with asymptomatic OLP, multiple or extensive skin lesions of lichen planus, uncontrolled diabetes mellitus, or hypertension were excluded.</P>
<P>Group A: randomised 25; analysed 23</P>
<P>Group B: randomised 24; analysed 23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 12:00:54 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: betamethasone 5 mg as a single daily dose orally on 2 consecutive days every week (3 months), than 4 mg (1 month), then 3 mg (1 month), then 2 mg (1 month)</P>
<P>Group B: triamcinolone acetonide (0.1%) oral paste, 3 times daily during the first 3 months, followed by twice daily application in the fourth month, once daily application in the fifth month, and alternate day application during the sixth month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 12:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (semi-quantitative scoring system), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:48:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mousavi-2009">
<CHAR_METHODS MODIFIED="2010-11-03 12:04:49 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Iran</P>
<P>Number of centres: 1</P>
<P>Recruitment period: September 2006-July 2007</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients were included if they were between 18 and 65 years old and did not suffer from another acute or chronic disease of the oral mucosa. The patients were required to have oral lesions of at least 10 mm in their longest dimension, and had the mind and general symptom of Ignatia.</P>
<P>Exclusion criteria: patients were excluded from the study if they had concurrent clinical conditions that could pose a health risk, including serious liver, kidney, and heart dysfunctions. Pregnant or nursing women and patients who had therapy for OLP within the 4 weeks before the study were excluded.</P>
<P>Group A: randomised 15; analysed 15</P>
<P>Group B: randomised 15; analysed 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: Ignatia in 30 C dilution, in liquid form, diluted in 100 ml of water in a single dose, for 4 months</P>
<P>Group B: a single placebo globule diluted in 100 ml of water, for 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 12:05:50 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (lesion size)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:49:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nolan-2009">
<CHAR_METHODS MODIFIED="2010-11-03 12:06:36 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: UK</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: financial support and drug provided by drug manufacturer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histopathological diagnosis of OLP participated in the study. Patients were enrolled consecutively and all had atrophic-ulcerative lesions. Patients had to present with pain/discomfort.</P>
<P>Exclusion criteria: patients were excluded from the study if they were taking systemic chemotherapy, immunosuppressant drugs associated with lichenoid reactions or where suffering from malignant disease.</P>
<P>Group A: randomised 62; analysed 56</P>
<P>Group B: randomised 62; analysed 57</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:52:17 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: Topical hyaluronic acid 0.2%, up to 5 times a day for 28 days</P>
<P>Group B: placebo, up to 5 times a day for 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 12:07:30 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical score (erosive area), functional score (eating)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:50:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passeron-2007">
<CHAR_METHODS MODIFIED="2010-11-10 15:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: France</P>
<P>Number of centres: 1</P>
<P>Recruitment period: December 2004-April 2005</P>
<P>Funding source: drug provided by manufacturer and financial support from Centre Hospitalier et Universitaire de Nice</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:50:17 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: confirmation of the diagnosis of OELP by histological examination of an oral biopsy specimen and a clinical score higher than 3.</P>
<P>Exclusion criteria: patients younger than 18 years, pregnancy or breastfeeding malignancy, severe or recurrent infections, uncontrolled chronic disorders, congenital or acquired immunosuppression, and concomitant treatments potentially effective on OELP, such as antimalarial agents, oral retinoids, corticosteroids, or immunosuppressive drugs.</P>
<P>Group A: randomised 6; analysed 6</P>
<P>Group B: randomised 6; analysed 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 12:09:10 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: pimecrolimus 1% twice daily for 4 weeks</P>
<P>Group B: placebo twice daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:50:22 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (5-grade scale), clinical score (erosive area)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-05 14:19:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:51:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodstrom-1994">
<CHAR_METHODS MODIFIED="2010-11-03 12:10:09 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Sweden</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: consecutive patients with clinical and histological diagnosis of OLP according to WHO recommendations.</P>
<P>Exclusion criteria: patients with lesions adjacent to buccal or lingual amalgam fillings.</P>
<P>Group A: randomised 20; analysed 17</P>
<P>Group B: randomised 20; analysed 20<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 12:11:06 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: clobetasol propionate 0.05% in orabase (50/50) twice a day for the first 3 weeks, once a day for the second 3 weeks, once every other day for the third 3 weeks (total 9 weeks)</P>
<P>Group B: triamcinolone acetonide 0.1% ointment twice a day for the first 3 weeks, once a day for the second 3 weeks, once every other day for the third 3 weeks (total 9 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:51:30 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (4-grade score), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-05 14:32:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:52:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<CHAR_METHODS MODIFIED="2011-06-14 16:51:57 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Spain</P>
<P>Number of centres: 1</P>
<P>Recruitment period: October 2007-September 2009</P>
<P>Funding source: unspecified, drug provided by manufacturer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histological diagnosis of OLP (WHO criteria), no topical treatment for OLP in the last 2 weeks, or in the last 4 weeks in the case of systemic therapies.</P>
<P>Exclusion criteria: allergy to some ingredient of the product, drugs capable of inducing lichenoid reactions, OLP lesions in contact with silver amalgam fillings, presence of dysplasia in the histopathological study of OLP, and presence of extraoral lesions.</P>
<P>Group A: randomised 32; analysed 31</P>
<P>Group B: randomised 32; analysed 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:52:48 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: aloe vera in a transparent aqueous suspension (70%), 0.4 ml applied in the mouth three times a day, keeping it within the oral cavity for 1 min, for 12 weeks</P>
<P>Group B: placebo (formulation identical to that of the study product but containing no aloe vera), 0.4 ml applied in the mouth three times a day, keeping it within the oral cavity for 1 min, for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom), treatment response (Carrozzo), quality of life (OHIP-49), anxiety and depression (HAD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:55:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swift-2005">
<CHAR_METHODS MODIFIED="2010-11-03 12:12:26 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: USA</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with signs and symptoms of oral erosive lichen planus, diagnosis was confirmed by biopsies submitted for routine histology and direct immunofluorescence.</P>
<P>Exclusion criteria: history of drug induced lichenoid lesions, malignancy, serious active or recurrent infections, severe heart disease, severe respiratory disease, diabetes mellitus, uncontrolled or severe hypertension, active peptic ulcer disease, active inflammatory gastrointestinal disease, significant renal disease resulting in serum creatinine levels above normal, significant liver disease resulting in liver enzymes greater than or equal to twice normal bilirubin, or alkaline phosphatase levels greater than 1.5 times normal at baseline. Also excluded were patients with haemoglobin values less than 9 gm/dl, a white blood cell count below 3000 mm³, and women who were pregnant.</P>
<P>Group A: randomised 10; analysed 10 (see notes)</P>
<P>Group B: randomised 10; analysed 10 (see notes)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 16:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: pimecrolimus cream 1%, twice daily, for 4 weeks</P>
<P>Group B: placebo, twice daily, for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 12:13:58 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (weighted area)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-07 14:32:54 +0000" MODIFIED_BY="[Empty name]">
<P>Quote: "Two participants were dropped from the study by their request prior to the mid-point examination, one because of systemic health problems and one due to scheduling conflicts. These subjects were replaced with other participants who were given the original group assignment."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:56:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volz-2008">
<CHAR_METHODS MODIFIED="2011-06-14 16:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Germany</P>
<P>Number of centres: 1</P>
<P>Recruitment period: August 2004-May 2006</P>
<P>Funding source: one of the authors is an employee of the manufacturer of the drug tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:56:33 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinically and histologically confirmed EOLP, painful lesions, no topical treatment for 2 weeks and no systemic therapy of OLP for 4 weeks before study start.</P>
<P>Exclusion criteria: pregnant or breastfeeding women, immunodeficiency or human immunodeficiency virus infection, current malignancy or malignancy in history, use of corticosteroids or other immunosuppressive drugs, known renal or hepatic insufficiency, and known allergy to macrolide antibiotics.</P>
<P>Group A: randomised 10; analysed 10</P>
<P>Group B: randomised 10; analysed 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-03 12:15:33 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: pimecrolimus cream 1%, twice daily, for 30 days                       </P>
<P>Group B: placebo, twice daily, for 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 12:15:53 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (composite score), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:58:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Voute-1993">
<CHAR_METHODS MODIFIED="2011-06-14 16:57:23 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: The Netherlands</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: ointments were provided by manufacturer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:58:01 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical features, history, histopathologic and immunofluorescence microscopy, non-use of medication and the absence of oral mucosal lesions other than LP.</P>
<P>Exclusion criteria: unclear.</P>
<P>Group A: randomised 20; analysed 20</P>
<P>Group B: randomised 20; analysed 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-12 10:29:25 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: fluocinonide in adhesive cream (0.025%) at least 6 times a day, for 9 weeks</P>
<P>Group B: placebo at least 6 times a day, for 9 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:58:14 +0100" MODIFIED_BY="[Empty name]">
<P>Pain (5-grade score), clinical score (5-grade score)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 16:59:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wei-2003">
<CHAR_METHODS MODIFIED="2010-11-03 12:58:21 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: China</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 16:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical demonstration of hyperemic OLP, pathologic examination confirmed the diagnosis of OLP, with a history of OLP for at least 3 months.</P>
<P>Exclusion criteria: OLP did not locate in the buccal mucosa, with other oral mucosa diseases or systematic diseases, first onset OLP or history less than 3 months, already taking local or systematic therapy in the past 3 months, OLP after the treatment of orthodontics and metallic full crown.</P>
<P>Group A: randomised 37; analysed 37</P>
<P>Group B: randomised 20; analysed 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-21 09:19:59 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: alternative use of Mycostatin paste and dexamethasone paste (twice daily each), for 6 weeks</P>
<P>Group B: dexamethasone paste (four times daily each), for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 16:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical score (4-grade score)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 17:01:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiong-2009">
<CHAR_METHODS MODIFIED="2010-11-03 13:01:34 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: China</P>
<P>Number of centres: 1</P>
<P>Recruitment period: July 2005-January 2006</P>
<P>Funding source: this study was supported by grants from the National Natural Science Foundation of China (No.30872873, No.30572041) and the Program for New Century Excellent Talents in University</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 17:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: erosive area not exceeding 1 cm²; disease process exceeding 2 months; and normal physical examination before medication (including complete blood cell count and renal and hepatic clinical chemistry examination, urine and stool routine test, blood pressure examination, ultrasonic examination of abdomen, X-ray of chest, and ECG).</P>
<P>Exclusion criteria: those with severe systemic diseases or other severe oral mucous diseases; those taking immunopotentiating or immunosuppressive agents during the previous 3 months; those having topical treatment within a week; those with lichenoid reaction caused by the amalgam fillings or certain drugs; those on gestation or lactation period; and those not taking drugs under the medical orders or not finishing the return visits and follow-up review.</P>
<P>Group A: randomised 31; analysed 28</P>
<P>Group B: randomised 25; analysed 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 17:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: Bacillus Calmette-Guerin polysaccharide nucleic acid, 0.5 ml intralesional injection every other day, until either erosive lesion disappeared or for 2 weeks. Total 6 injections</P>
<P>Group B: 10 mg triamcinolone acetonide (0.25 ml from solution 40 mg/ml) mixed 0.25 ml of 2% lidocaine solution, intralesional injection, once a week, for 2 weeks. Total 2 injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 13:02:47 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (erosive area), adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 17:03:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2002">
<CHAR_METHODS MODIFIED="2010-11-03 13:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: China</P>
<P>Number of centres: 1</P>
<P>Recruitment period: unclear</P>
<P>Funding source: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 17:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical and histopathological diagnosis of OLP.</P>
<P>Exclusion criteria: systemic diseases, other oral mucosa diseases or advanced periodontal diseases; any immune-modulating drug in the last 3 months.</P>
<P>Group A: randomised 20; analysed 20</P>
<P>Group B: randomised 19; analysed 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 17:03:28 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: three-step treatment by traditional and Western medicine combined (herbal topical and decoction plus prednisone 5 to 10 mg tid chlorphenamine 4 mg tid, vitamin C 0.1g tid). Herbal treatment applied topically, followed by herbal decoction plus decreasing doses of western medicine, followed by herbal decoction only. Treatment duration 6 weeks</P>
<P>Group B: Western medicine (prednisone 5 to 10 mg tid, chlorphenamine 4 mg tid, Vitamin C 0.1g tid), dosage gradually decreased over 4-week period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 17:03:31 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical score (4-grade score), relapse rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-14 17:08:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoke-2006">
<CHAR_METHODS MODIFIED="2011-06-14 17:08:18 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: RCT</P>
<P>Conducted in: Singapore, South Korea, India, Thailand</P>
<P>Number of centres: 4: Singapore, Seoul (South Korea), Madras (India), Bangkok (Thailand)</P>
<P>Recruitment period: 2000-2003</P>
<P>Funding source: National Medical Research Council, Ministry of Health, Singapore. Trident Pharm Pte Ltd (Singapore) assisted with the distribution of Kenalog to the overseas centres; Novartis Pte Ltd (Singapore) provided Sandimmun Neoral (cyclosporine) at cost for the trial and assisted in coordinating the trial supplies at the overseas centres</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 17:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically confirmed OLP and with both clinical signs and symptoms of their OLP requiring treatment were eligible for the trial.</P>
<P>Exclusion criteria: treated previously by either of the trial medications and had worsened during that treatment or if they had uncontrolled or severe hypertension, serious active or recurrent infections, severe respiratory, renal, or heart disease, recent history of malignancy, insulin dependent diabetes, active peptic ulcer disease, active inflammatory gastrointestinal disease, or pregnancy.</P>
<P>Group A: randomised 71; analysed 71</P>
<P>Group B: randomised 68; analysed 68</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:52:36 +0000" MODIFIED_BY="[Empty name]">
<P>Group A: cyclosporine solution 0.1%, 3 times daily, for 8 weeks</P>
<P>Group B: triamcinolone acetonide 0.1% orabase, 3 times daily, for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 13:11:40 +0000" MODIFIED_BY="[Empty name]">
<P>Pain (VAS), clinical score (Thongprasom)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-06-14 16:22:18 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-06-19 08:55:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boisnic-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 08:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>The author informed us that the study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:00:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bouloc-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>The study included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-19 08:55:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buajeeb-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 08:55:47 +0100" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-19 08:56:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buajeeb-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 08:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-10 10:52:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-10 10:52:54 +0000" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients, not all patients underwent biopsy and included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-20 15:55:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cilurzo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-20 15:55:12 +0000" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-03 05:54:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delavarian-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-03 05:54:39 +0100" MODIFIED_BY="[Empty name]">
<P>The study included OLP with psychiatric disorders only and it is not specified whether all patients are symptomatic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:23:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giustina-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:31:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glade-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:31:10 +0100" MODIFIED_BY="[Empty name]">
<P>The study included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:32:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenspan-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:32:10 +0100" MODIFIED_BY="[Empty name]">
<P>Not all patients included in the study underwent biopsy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:34:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunther-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:34:11 +0100" MODIFIED_BY="[Empty name]">
<P>The study was not a randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:35:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hantash-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>The study included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-14 16:22:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harpenau-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-14 16:22:18 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-19 08:57:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hersle-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 08:57:43 +0100" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:40:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kellett-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not all patients underwent biopsy and the study included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 14:41:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laurberg-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 14:41:21 +0100" MODIFIED_BY="[Empty name]">
<P>The study included patients with lichen planus without oral lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-26 11:01:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCaughey-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-26 11:01:52 +0000" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-19 08:58:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Radfar-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-19 08:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>The study included asymptomatic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:24:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tyldesley-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:24:19 +0100" MODIFIED_BY="[Empty name]">
<P>Not all patients included in the study underwent biopsy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-06-14 17:15:30 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-06-14 17:14:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jajarm-2011">
<CHAR_METHODS MODIFIED="2011-06-14 17:09:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 17:09:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised 30 patients with biopsy-proven OLP; analysed 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 17:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: laser irradiation using a 630 nm, 10 mW continuous wave laser (exposure time, 2.5 min; fluence 1.5 J/cm² per session; irradiance 10 mW/cm²; one illumination point; area 1 cm²), twice a week for a maximum of 10 sessions</P>
<P>Group B: dexamethasone (0.5 mg in 5 ml water) mouthwash for 5 minutes, followed 30 minutes later with 30 drops (100,000 units), nystatin for 5 minutes. Treatment repeated four times daily for 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 17:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-14 17:14:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Javadzadeh-2008">
<CHAR_METHODS MODIFIED="2011-06-14 17:14:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial</P>
<P>Double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-14 17:14:40 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients, clinical and histological diagnosis of atrophic/erosive OLP on the basis of World Health Organisation criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 17:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: 5 ml of the new mouthwash [containing clobetasol (Sigma) Ketoconazole (Sigma) and amitriptyline (Sigm)]</P>
<P>Group B: dexamethasone tablet, nystatin drop and diphenhydramine syrup.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-14 17:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 16:12:17 +0000" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-21 13:45:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005">
<CHAR_METHODS MODIFIED="2010-06-21 13:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-21 13:45:10 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-21 13:45:12 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-21 13:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-06-14 17:15:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2010">
<CHAR_METHODS MODIFIED="2011-06-14 17:15:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised using a random number table and allocated by sealed envelopes</P>
<P>Double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-08 02:35:09 +0000" MODIFIED_BY="[Empty name]">
<P>
69 patients with biopsy proven OLP
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-14 17:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: thalidomide 1% paste was applied 3 times daily for 1 week</P>
<P>Group B: dexamethasone 0.043% paste was applied 3 times daily  for 1 week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-08 02:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
Adverse effects reported
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 16:12:44 +0000" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-07-09 15:47:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-06-15 11:18:29 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-06-14 17:08:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:27:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quote: "computer generated random number tables".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:32:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>Quote: "The randomization sequence was generated [...] using random number generator".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:33:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>Quote: "Randomization was performed by using a simple random numbers table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:34:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>Quote: "computer-generated random number tables".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:35:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>Quote: "Computer randomization".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:38:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>Quote: "Patients were assigned [...] with Table of random numbers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>Authors referred that the allocation list was computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:40:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>Quote: "randomization sequence was generated by use of a randomization table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>Quote: "A table of random numbers was used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:44:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>Quote: "pre-determined randomization list stratified by sex".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:44:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>Quote: "allocation sequence was generated using software available on line".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:46:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>Treatement assigned by means of a random number table (personal communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>Quote: "generated from random table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Quote: "Randomization was performed using computer-generated random number tables".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:49:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:50:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>Quote: "Randomization into 2 groups was done by draw lots, with equilibration every 4 subjects".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:51:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>Comment: "randomized" insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:53:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>Quote: "randomization sequence was generated by an operator external to the study using the random number generator in Microsoft Excel".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:55:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>Quote: "randomized into two equal groups". </P>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>Quote: "Randomization was performed by Novartis using a validated system that automated the random assignment of treatment groups to randomization numbers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:58:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>Quote: "randomized". </P>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 15:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>Method of sequence generation not described by translator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:01:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>Quote: "random number table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:04:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>Quote: "randomized trial". </P>
<P>Method of sequence generation not described by translator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:08:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>Quote: "Central randomization office of the Clinical trials and Epidemiology Research Unit, Singapore".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-06-14 17:08:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:27:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:29:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-05 16:03:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quote: "the medication, packed by a pharmacist, was distributed in indistinguishable containers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:33:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>Quote: "Code was kept at the Faculty of Pharmaceutical Sciences until completion of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:34:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>Authors referred that the allocation list was hidden and allocation performed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:35:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:40:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:41:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>Quote: "Randomization numbers in sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:43:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>Quote: "The sequence was concealed until the effect of both intervention was analysed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:44:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:44:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>Quote: "sequence was hidden from the researchers determining patient eligibility".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:47:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>Quote: "patients were allocated using sealed envelope method".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:49:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:50:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:51:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>Comment: randomisation undertaken by person(s) external to the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:55:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>Quote: "All personnel directly involved in the conduct of the study remained blinded to the treatment assignment until all patients had completed the study and all data had been retrieved and finalized for analysis".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:58:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:00:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:01:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:06:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:08:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>Quote: "Once eligibility had been confirmed [...] patients were randomly assigned[...] by telephone (Singapore and South Korea) or sealed envelope (India and Thailand)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-06-14 17:01:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:27:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:29:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>Quote: "observer blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:30:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>Quote: "Both patients and investigators were blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:33:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:34:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:38:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>Quote "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:39:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>Authors referred that the study was double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-13 17:21:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>Quote: "Single blind" (assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:43:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>Blinding not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:44:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>Blinding not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-13 17:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-13 17:22:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Quote: "Single blind".</P>
<P>Comment: it is unclear who is blind, probably patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:49:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:51:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>Quote: "Both patients and investigators were blind to the treatment assignment" and "The data in all cases were collected by a single investigator blinded to the group to which the patient belonged".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:55:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>Quote: "Both the patients and the examiner were masked to the type of medication dispensed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 16:58:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 17:00:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>Quote: "Double blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-14 17:01:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>Quote: "blind-assessed trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-13 17:23:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-13 17:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-15 11:18:29 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:25:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>No missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:29:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>5 lost to follow-up. Reasons given and numbers similar in each group. Unlikely to have resulted in bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-15 11:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>3 from group A and 2 from group B were excluded from the analysis due to 'personal reasons'. Unlikely to have introduced a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:32:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:33:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>No missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:34:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>1 patient from Group A lost to follow-up and excluded from analysis. Unlikely to have introduced a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:35:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>Comment: no missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:38:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>Comment: no missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:39:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>Comment: no missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:40:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>Comment: no missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:41:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>5 patients dropped out of the study during fluticasone treatment (3 in group A and 2 in group B) and this is likely to have introduced a bias as ITT analysis was not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:44:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>Comment: no missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>5/35 (14%) of patients excluded from analysis. In group A, 2 ran out of product and did not seek further supply and 1 was lost to follow-up. In group B, 1 developed a papilloma and 1 was lost to follow-up. Possible source of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 12:03:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>2/18 (11%) of patients randomised were excluded from analysis, but in a randomised split-mouth design, this loss of data is unlikely to cause a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:47:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:49:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>No missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-20 15:48:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>11/124 (9%) excluded from analysis due to protocol violation. It is not stated which groups these patients were from and the numbers of patients analysed per group is not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:50:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>1 patient lost to follow-up in placebo group but ITT analysis done using last score carried forward.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-20 15:48:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>3/20 in clobetasol group, and none in comparison group excluded from analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>Group A: randomised 32; analysed 31.</P>
<P>Group B: randomised 32; analysed 24.</P>
<P>Higher rate of drop-out in the placebo group which may have introduced a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-20 15:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>2 patients (10%) randomised to treatment were dropped for reasons apparently unrelated to allocated treatment, and they were replaced by 2 more patients. Unclear whether dropped patients were in treatment or placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 16:58:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>No missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 17:00:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>No missing data. All randomised participants included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 17:01:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>3/31 (10%) of BCG group did not complete treatment and were excluded from analysis due to swelling and burning at injection site. All triamcinolone group included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 17:06:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>No missing data. All randomised participants included in result analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 17:09:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>ITT analysis (7 and 5 from experimental and control groups were lost to follow-up and 6 and 5 respectively stopped taking the medications, but all were included in the analysis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-06-14 17:06:43 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:30:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:32:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (standard deviations are missing) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:33:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:34:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:38:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (adverse effects) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>One or more outcomes of interest are reported incompletely so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:40:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (standard deviations are missing) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:41:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:43:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>Comment: data from this cross-over study are not analysed as paired and therefore they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:44:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>Pain, clinical response to treatment and adverse effects reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (standard deviations are missing) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:49:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (standard deviations are missing) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:50:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:51:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>Comment: one or more outcomes of interest are reported incompletely (standard deviations are missing) so data cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:54:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>Comment: wide range of outcomes reported including adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:56:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>One or more outcomes of interest are reported incompletely (standard deviations are missing) so they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:58:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:00:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:01:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:06:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 15:48:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>Comment: Clinical improvement, pain and adverse effects reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-06-14 17:09:05 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Agha_x002d_Hosseini-2010">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campisi-2004">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:43:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 16:32:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chainani_x002d_Wu-2007">
<DESCRIPTION>
<P>A total of five patients used topical corticosteroids during the study. Of these, two were in the placebo group and three were in the curcuminoids group (one of whom dropped out of the study after 4 weeks, at the second follow-up visit). Unlikely to have caused a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:43:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choonhakarn-2008">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conrotto-2006">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corrocher-2008">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisen-1990">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaeta-1994">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghabanchi-2009">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorouhi-2007">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hegarty-2002">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laeijendecker-2006">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lodi-2007">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundquist-1995">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malhotra-2008">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 09:19:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nolan-2009">
<DESCRIPTION>
<P>Trial funded by Pharma, allocation process unclear and numbers included in analysis unclear. Hyaluronic acid reported to be beneficial although no difference between active and placebo groups. Possible bias due to funding source.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 09:19:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passeron-2007">
<DESCRIPTION>
<P>Small study, lacking power, pimecrolimus supplied by Pharma company with some differences between groups at baseline. Possible bias due to funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:44:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodstrom-1994">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:45:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salazar_x002d_Sanchez-2010">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 15:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swift-2005">
<DESCRIPTION>
<P>Comment: two patients were dropped from the study and replaced with other two (see notes). Substantial differences between the groups in baseline values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 15:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volz-2008">
<DESCRIPTION>
<P>During the second month open label treatment with pimecrolimus for those who had not improved during the blinded treatment phase, and no treatment for the remainder. Relapse data unblinded and may be subject to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voute-1993">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:45:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2003">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 15:48:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xiong-2009">
<DESCRIPTION>
<P>Groups appear similar at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 16:45:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2002">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-14 17:09:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoke-2006">
<DESCRIPTION>
<P>Groups appear to be comparable at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-07-09 15:49:02 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-06-15 09:08:03 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-04-14 17:15:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any intervention vs placebo</NAME>
<CONT_OUTCOME CHI2="5.116898691499024" CI_END="-0.24773927905285553" CI_START="-1.2894548591230217" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7685970690879387" ESTIMABLE="YES" I2="41.37073682963356" I2_Q="58.99904229744539" ID="CMP-001.01" MODIFIED="2011-04-04 16:11:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16343489246723908" P_Q="0.08725094906236852" P_Z="0.003825597740218875" Q="4.877934838764481" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="48" UNITS="" WEIGHT="300.0" Z="2.8921955337059204">
<NAME>Pain (mean score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.23896385273454318" CI_END="0.9094069859152365" CI_START="-0.8495271050785447" DF="1" EFFECT_SIZE="0.029939940418345936" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2011-03-15 11:03:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.624955504875033" P_Z="0.9468017482987736" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.06672359722822678">
<NAME>Pimecrolimus</NAME>
<CONT_DATA CI_END="1.3843784967803003" CI_START="-2.064378496780301" EFFECT_SIZE="-0.3400000000000003" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.41" MODIFIED="2009-12-16 11:56:04 +0000" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="2.29" SD_2="1.58" SE="0.8798011138888153" STUDY_ID="STD-Swift-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="26.012011916330785"/>
<CONT_DATA CI_END="1.1824426603669411" CI_START="-0.8624426603669413" EFFECT_SIZE="0.15999999999999992" ESTIMABLE="YES" MEAN_1="0.83" MEAN_2="0.67" MODIFIED="2011-03-15 11:03:47 +0000" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="0.98" SD_2="0.82" SE="0.5216640042530569" STUDY_ID="STD-Passeron-2007" TOTAL_1="6" TOTAL_2="6" WEIGHT="73.98798808366921"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.49065791281264115" CI_START="-2.8906579128126415" DF="0" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2011-03-15 13:46:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16418029953372107" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="24" WEIGHT="100.0" Z="1.3911488324301295">
<NAME>Aloe vera</NAME>
<CONT_DATA CI_END="0.49065791281264115" CI_START="-2.8906579128126415" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.7" MODIFIED="2011-03-14 15:22:13 +0000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="3.0" SD_2="3.3" SE="0.8625964181731578" STUDY_ID="STD-Salazar_x002d_Sanchez-2010" TOTAL_1="31" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5004273777823839" CI_START="-1.8995726222176166" DF="0" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2011-03-15 13:46:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.738267707546223E-4" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="3.3619908880831555">
<NAME>Cyclosporin</NAME>
<CONT_DATA CI_END="-0.5004273777823839" CI_START="-1.8995726222176166" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.6" MODIFIED="2011-02-09 11:17:30 +0000" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="0.56" SD_2="0.84" SE="0.35693136595149494" STUDY_ID="STD-Eisen-1990" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0437412754123905" CI_START="-1.3637412754123905" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-04-14 17:01:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6956996596501068" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.00000000000001" Z="0.39113201303544115">
<NAME>Pain on feeding (mean score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0437412754123905" CI_START="-1.3637412754123905" DF="0" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2011-04-14 17:01:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6956996596501068" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.00000000000001" Z="0.39113201303544115">
<NAME>Pimecrolimus</NAME>
<CONT_DATA CI_END="2.0437412754123905" CI_START="-1.3637412754123905" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="1.33" MODIFIED="2011-04-14 17:01:16 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="1.63" SD_2="1.37" SE="0.8692717258333745" STUDY_ID="STD-Passeron-2007" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="100" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-14 16:59:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="108" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-10 12:26:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Pimecrolimus</NAME>
<DICH_DATA CI_END="4.0042174346735635" CI_START="0.6937130221062111" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6025176522525849" LOG_CI_START="-0.15882015301987223" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2011-03-10 12:26:05 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Passeron-2007" TOTAL_1="6" TOTAL_2="6" VAR="0.20000000000000004" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-15 13:52:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Aloe vera</NAME>
<DICH_DATA CI_END="2.1026724722440044" CI_START="1.17440437714328" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.32277162904629664" LOG_CI_START="0.06981766124163974" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2011-03-10 12:26:41 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.14858641283079044" STUDY_ID="STD-Choonhakarn-2008" TOTAL_1="27" TOTAL_2="27" VAR="0.022077922077922085" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="48" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-15 13:52:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Hyaluronic acid</NAME>
<DICH_DATA CI_END="1.1809665691657516" CI_START="0.882413373632241" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" LOG_CI_END="0.07223760376733593" LOG_CI_START="-0.054327918461483146" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2011-03-10 12:26:25 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.07434521426664759" STUDY_ID="STD-Nolan-2009" TOTAL_1="56" TOTAL_2="56" VAR="0.005527210884353741" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="12" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-15 13:52:36 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Purslane</NAME>
<DICH_DATA CI_END="1.9226286927929082" CI_START="1.0252712899735783" EFFECT_SIZE="1.404" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.2838954193183256" LOG_CI_START="0.01083879626924724" LOG_EFFECT_SIZE="0.14736710779378642" MODIFIED="2011-03-10 12:26:53 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.16039481203111192" STUDY_ID="STD-Agha_x002d_Hosseini-2010" TOTAL_1="19" TOTAL_2="17" VAR="0.025726495726495727" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-04-14 16:59:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (areas of ulceration)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2009-12-03 14:21:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Pimecrolimus</NAME>
<CONT_DATA CI_END="6.209265102930026" CI_START="-4.289265102930024" EFFECT_SIZE="0.9600000000000004" ESTIMABLE="YES" MEAN_1="3.47" MEAN_2="2.51" MODIFIED="2009-12-03 09:50:41 +0000" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="7.32" SD_2="4.26" SE="2.678245694479877" STUDY_ID="STD-Swift-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2009-12-03 14:20:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Hyaluronic acid</NAME>
<CONT_DATA CI_END="-0.250041065476361" CI_START="-0.749958934523639" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="13.5" MODIFIED="2009-12-03 14:10:14 +0000" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="0.7" SD_2="0.72" SE="0.12753241207250907" STUDY_ID="STD-Nolan-2009" TOTAL_1="62" TOTAL_2="62" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.098647260480359" CI_END="-0.9432537320861406" CI_START="-1.4299480849987574" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.186600908542449" ESTIMABLE="YES" I2="77.09687160557996" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-04-14 16:59:18 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.004428075260091924" P_Q="0.7459147111822636" P_Z="1.2109414492326763E-21" Q="0.5862881035910122" RANDOM="NO" SCALE="3.75" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="79" UNITS="" WEIGHT="300.0" Z="9.557107169407706">
<NAME>Signs (mean clinical score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.512359156889346" CI_END="-0.8657896188442726" CI_START="-1.4115861759857848" DF="1" EFFECT_SIZE="-1.1386878974150287" ESTIMABLE="YES" I2="92.0079020473977" ID="CMP-001.05.01" MODIFIED="2011-04-01 09:56:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.042752371418157E-4" P_Z="2.883732163624634E-16" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="51" WEIGHT="100.00000000000001" Z="8.178092145738644">
<NAME>Aloe vera</NAME>
<CONT_DATA CI_END="-1.0685032375002468" CI_START="-1.671496762499753" EFFECT_SIZE="-1.3699999999999999" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="2.44" MODIFIED="2009-12-03 14:27:53 +0000" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="0.55" SD_2="0.58" SE="0.15382770544659036" STUDY_ID="STD-Choonhakarn-2008" TOTAL_1="27" TOTAL_2="27" WEIGHT="81.92874198554914"/>
<CONT_DATA CI_END="0.5519579815250472" CI_START="-0.7319579815250473" EFFECT_SIZE="-0.09000000000000008" ESTIMABLE="YES" MEAN_1="1.74" MEAN_2="1.83" MODIFIED="2011-02-01 15:28:53 +0000" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="1.26" SD_2="1.16" SE="0.3275356009542674" STUDY_ID="STD-Salazar_x002d_Sanchez-2010" TOTAL_1="31" TOTAL_2="24" WEIGHT="18.071258014450876"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.9594121594425707E-31" CI_END="-0.6000081003362334" CI_START="-2.199991899663766" DF="0" EFFECT_SIZE="-1.3999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-001.05.02" MODIFIED="2011-04-01 09:56:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="6.036441981547977E-4" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="3.4299717028501755">
<NAME>Cyclosporin</NAME>
<CONT_DATA CI_END="-0.6000081003362336" CI_START="-2.1999918996637664" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.7" MODIFIED="2011-02-09 11:18:58 +0000" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="0.28" SD_2="1.12" SE="0.4081666326391711" STUDY_ID="STD-Eisen-1990" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6238869074722113" CI_START="-2.0761130925277884" DF="0" EFFECT_SIZE="-1.3499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" MODIFIED="2011-04-01 09:56:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.684402163670658E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.643993485805122">
<NAME>Flucinonide</NAME>
<CONT_DATA CI_END="-0.6238869074722113" CI_START="-2.0761130925277884" EFFECT_SIZE="-1.3499999999999999" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="2.8" MODIFIED="2009-12-03 14:19:24 +0000" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="1.23" SD_2="1.11" SE="0.37047267105685405" STUDY_ID="STD-Voute-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="35.175759774439" CI_END="2.077485500626752" CI_START="1.4312753761465749" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7243705638141154" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="57" I2="82.94279913646673" I2_Q="59.085357658574445" ID="CMP-001.06" LOG_CI_END="0.3175380013997024" LOG_CI_START="0.1557231996823783" LOG_EFFECT_SIZE="0.23663060054104035" METHOD="MH" MODIFIED="2011-04-14 17:15:16 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="3.984449256422273E-6" P_Q="0.04436654440361365" P_Z="9.906366992676082E-9" Q="9.776451096946412" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="121" TOTAL_2="112" WEIGHT="500.0" Z="5.7323242345989875">
<NAME>Clinical Improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22825434537522385" CI_END="4.009477149117011" CI_START="0.9976363129743492" DF="1" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.6030877426804893" LOG_CI_START="-0.0010277513525269093" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-04-01 09:56:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6328212574449372" P_Z="0.05078462500788067" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.9532952079371984">
<NAME>Pimecrolimus</NAME>
<DICH_DATA CI_END="8.191588722274396" CI_START="0.7629777582711312" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9133681394165956" LOG_CI_START="-0.11748812207252034" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-04-01 09:56:17 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Passeron-2007" TOTAL_1="6" TOTAL_2="6" VAR="0.3666666666666667" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="4.1385431753839645" CI_START="0.7399946962534389" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6168474903390713" LOG_CI_START="-0.13077139296648244" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2011-03-10 12:22:39 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.4391550328268399" STUDY_ID="STD-Volz-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.1928571428571428" WEIGHT="66.66666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.17673759531752" CI_END="1.624282589462079" CI_START="1.1034986905710087" DF="1" EFFECT_SIZE="1.3388030888030888" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="35" I2="90.17366822487281" ID="CMP-001.06.02" LOG_CI_END="0.21066158917085964" LOG_CI_START="0.04277182215728166" LOG_EFFECT_SIZE="0.12671670566407064" MODIFIED="2011-03-15 13:46:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0014222476143647134" P_Z="0.0030902983707325367" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="51" WEIGHT="100.0" Z="2.9586100899294854">
<NAME>Aloe vera</NAME>
<DICH_DATA CI_END="2.691139859403072" CI_START="1.2816054802152725" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.42993626877402064" LOG_CI_START="0.1077543558111393" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2011-03-10 12:22:59 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.1892512505005867" STUDY_ID="STD-Choonhakarn-2008" TOTAL_1="27" TOTAL_2="27" VAR="0.03581603581603582" WEIGHT="37.16216216216216"/>
<DICH_DATA CI_END="1.2483980698774861" CI_START="0.8535392175535446" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.09635308854007082" LOG_CI_START="-0.06877651956880425" LOG_EFFECT_SIZE="0.013788284485633283" MODIFIED="2011-03-10 12:23:08 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.09699794920789631" STUDY_ID="STD-Salazar_x002d_Sanchez-2010" TOTAL_1="31" TOTAL_2="24" VAR="0.009408602150537633" WEIGHT="62.83783783783784"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.631846714913145" CI_START="1.303642048554553" DF="0" EFFECT_SIZE="5.666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="1.3914969732695117" LOG_CI_START="0.11515836004771117" LOG_EFFECT_SIZE="0.7533276666586115" MODIFIED="2011-04-14 17:15:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.02068738638094449" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="2.3136416620373614">
<NAME>Cyclosporine</NAME>
<DICH_DATA CI_END="24.631846714913145" CI_START="1.303642048554553" EFFECT_SIZE="5.666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.3914969732695117" LOG_CI_START="0.11515836004771117" LOG_EFFECT_SIZE="0.7533276666586115" MODIFIED="2011-03-10 12:21:16 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.7497276193845162" STUDY_ID="STD-Eisen-1990" TOTAL_1="8" TOTAL_2="8" VAR="0.5620915032679739" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2077529162028933" CI_START="1.0191357843928328" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.3439504670942347" LOG_CI_START="0.008232051017127732" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-04-04 15:01:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.03977448114441179" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.056083367569438">
<NAME>Flucinonide</NAME>
<DICH_DATA CI_END="2.2077529162028933" CI_START="1.0191357843928328" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.3439504670942347" LOG_CI_START="0.008232051017127732" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-04-04 15:01:52 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.19720265943665388" STUDY_ID="STD-Voute-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.03888888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.571109617848506" CI_START="1.6779257475446336" DF="0" EFFECT_SIZE="4.771929824561403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="1.1326153584340335" LOG_CI_START="0.2247727382893811" LOG_EFFECT_SIZE="0.6786940483617073" MODIFIED="2011-03-15 13:52:10 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0033841821231347354" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="2.9304988811798243">
<NAME>Purslane</NAME>
<DICH_DATA CI_END="13.571109617848506" CI_START="1.677925747544634" EFFECT_SIZE="4.771929824561403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.1326153584340335" LOG_CI_START="0.22477273828938119" LOG_EFFECT_SIZE="0.6786940483617073" MODIFIED="2011-03-10 12:23:25 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.533271248966415" STUDY_ID="STD-Agha_x002d_Hosseini-2010" TOTAL_1="19" TOTAL_2="17" VAR="0.2843782249742002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-14 16:59:13 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="16.69" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Clinical Improvement (split mouth)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-10 13:47:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Photochemotherapy (split mouth)</NAME>
<IV_DATA CI_END="3.8924128348667715" CI_START="1.205592043418743" EFFECT_SIZE="2.1662552812206535" ESTIMABLE="YES" ESTIMATE="0.773" LOG_CI_END="0.5902188959324557" LOG_CI_START="0.08120037308997174" LOG_EFFECT_SIZE="0.33570963451121366" MODIFIED="2011-03-10 13:47:54 +0000" MODIFIED_BY="[Empty name]" ORDER="87" SE="0.299" STUDY_ID="STD-Lundquist-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0826775962992802" CI_END="16.12996750426424" CI_START="1.2301931297360476" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.2076334924520153" LOG_CI_START="0.08997329728856188" LOG_EFFECT_SIZE="0.6488033948702886" METHOD="MH" MODIFIED="2011-04-14 16:59:11 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9938318615531961" P_Q="0.9311455604979224" P_Z="0.022874515917943608" Q="0.007465587532855612" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="89" WEIGHT="200.0" Z="2.275523978568663">
<NAME>Adverse Effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07491142837491498" CI_END="17.925405251372982" CI_START="1.0414783410759858" DF="2" EFFECT_SIZE="4.320754716981132" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="1.2534689828305265" LOG_CI_START="0.017650242647671125" LOG_EFFECT_SIZE="0.635559612739099" MODIFIED="2011-03-15 13:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9632370751082548" P_Z="0.043805279530601864" STUDIES="3" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="2.015949282032322">
<NAME>Pimecrolimus</NAME>
<DICH_DATA CI_END="72.90061470952946" CI_START="0.2519505084005082" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8627311903732706" LOG_CI_START="-0.5986847609624593" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2011-03-15 13:49:47 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.445847914020071" STUDY_ID="STD-Passeron-2007" TOTAL_1="6" TOTAL_2="5" VAR="2.0904761904761906" WEIGHT="26.415094339622645"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-03-15 13:50:26 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Swift-2005" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="24.528301886792455"/>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-03-15 13:51:38 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Volz-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="49.05660377358491"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.51175693739407" CI_START="0.25122659642848305" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="1.9978743940260948" LOG_CI_START="-0.5999343853540573" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-03-15 13:52:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29156201254705516" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.0547012125344188">
<NAME>Aloe Vera</NAME>
<DICH_DATA CI_END="99.51175693739407" CI_START="0.25122659642848294" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9978743940260948" LOG_CI_START="-0.5999343853540575" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-03-15 13:50:51 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Choonhakarn-2008" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-15 13:52:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Fluocinonide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-15 13:51:27 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.0" STUDY_ID="STD-Voute-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-15 13:52:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Purslane</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-15 13:50:18 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Agha_x002d_Hosseini-2010" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-04-07 11:54:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Topical steroids vs topical calcineurin inhibitors</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-04-04 16:28:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="126" TOTAL_2="124" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (mean score)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Calcineurin inhibitors</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2011-03-16 14:42:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus cyclosporin</NAME>
<CONT_DATA CI_END="0.4221288565519944" CI_START="-0.8374220391685864" EFFECT_SIZE="-0.20764659130829602" ESTIMABLE="YES" MEAN_1="1.84" MEAN_2="2.25" MODIFIED="2011-03-16 14:42:16 +0000" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="2.12" SD_2="1.74" SE="0.32131990833907087" STUDY_ID="STD-Conrotto-2006" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2011-03-16 14:42:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus tacrolimus</NAME>
<CONT_DATA CI_END="2.547654414847675" CI_START="0.8948059934587601" EFFECT_SIZE="1.7212302041532175" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="0.31" MODIFIED="2011-03-16 14:42:59 +0000" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="0.58" SD_2="0.48" SE="0.42165275342464764" STUDY_ID="STD-Corrocher-2008" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" MODIFIED="2011-03-16 14:43:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus cyclosporin</NAME>
<CONT_DATA CI_END="0.23682802570897948" CI_START="-0.4286882191312626" EFFECT_SIZE="-0.09593009671114155" ESTIMABLE="YES" MEAN_1="1.33" MEAN_2="1.56" MODIFIED="2011-03-16 14:43:56 +0000" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="2.33" SD_2="2.44" SE="0.16977767195972712" STUDY_ID="STD-Yoke-2006" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.04" MODIFIED="2011-03-16 14:44:31 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus pimecrolimus</NAME>
<CONT_DATA CI_END="0.5870683471431469" CI_START="-0.6526140180053118" EFFECT_SIZE="-0.03277283543108247" ESTIMABLE="YES" MEAN_1="-9.3" MEAN_2="-8.8" MODIFIED="2011-03-16 14:44:31 +0000" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="18.0" SD_2="11.1" SE="0.3162513125054631" STUDY_ID="STD-Gorouhi-2007" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0">
<FOOTNOTE>Measure is change in score from baseline</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:29:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcineurin inhib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3783459496545056" CI_START="0.9012426221776797" EFFECT_SIZE="1.1145510835913313" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.13935823438553482" LOG_CI_START="-0.04515827751316604" LOG_EFFECT_SIZE="0.047099978436184374" MODIFIED="2011-03-10 13:50:14 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.10838591246076142" STUDY_ID="STD-Conrotto-2006" TOTAL_1="19" TOTAL_2="20" VAR="0.011747506019951837" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2011-04-07 11:54:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="41.96" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="71" TOTAL_2="68" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (area of ulceration)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcineurin inhib</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2011-04-07 11:54:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus cyclosporin</NAME>
<CONT_DATA CI_END="-5.609448740963305" CI_START="-25.910551259036698" EFFECT_SIZE="-15.760000000000002" ESTIMABLE="YES" MEAN_1="4.91" MEAN_2="20.67" MODIFIED="2009-12-21 10:33:02 +0000" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="16.11" SD_2="39.69" SE="5.178947847564011" STUDY_ID="STD-Yoke-2006" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2011-04-04 16:29:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.86" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="75" TOTAL_2="76" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (mean clinical score)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcineurin inhib</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2011-03-16 14:46:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus cyclosporin</NAME>
<CONT_DATA CI_END="-0.2200179857252571" CI_START="-1.9799820142747426" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="1.95" MEAN_2="3.05" MODIFIED="2011-03-16 14:46:54 +0000" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.22" SD_2="1.57" SE="0.44897866553463667" STUDY_ID="STD-Conrotto-2006" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2011-03-16 14:47:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus tacrolimus</NAME>
<CONT_DATA CI_END="0.9903369023836797" CI_START="0.38966309761632023" EFFECT_SIZE="0.69" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="0.44" MODIFIED="2011-03-16 14:47:25 +0000" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="0.34" SD_2="0.51" SE="0.15323592920721954" STUDY_ID="STD-Corrocher-2008" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" MODIFIED="2011-03-16 14:48:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus pimecrolimus</NAME>
<CONT_DATA CI_END="0.40405692653325515" CI_START="-0.40405692653325515" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.7" MODIFIED="2011-03-16 14:48:06 +0000" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="0.7" SD_2="0.6" SE="0.206155281280883" STUDY_ID="STD-Gorouhi-2007" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.04" MODIFIED="2011-03-16 14:49:15 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus tacrolimus</NAME>
<CONT_DATA CI_END="1.0565449123533153" CI_START="0.24345508764668466" EFFECT_SIZE="0.6499999999999999" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="0.8" MODIFIED="2011-03-16 14:49:15 +0000" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="0.69" SD_2="0.62" SE="0.2074246851269154" STUDY_ID="STD-Laeijendecker-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:29:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="110" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Clinical Improvement</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcineurin inhib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="16" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:51:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus cyclosporin</NAME>
<DICH_DATA CI_END="1.4621109799899008" CI_START="0.8555203182853939" EFFECT_SIZE="1.118421052631579" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.16498033853699917" LOG_CI_START="-0.06776967166999638" LOG_EFFECT_SIZE="0.048605333433501395" MODIFIED="2011-03-16 14:51:27 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.13671850812672104" STUDY_ID="STD-Conrotto-2006" TOTAL_1="19" TOTAL_2="20" VAR="0.018691950464396284" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="18" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:52:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus tacrolimus</NAME>
<DICH_DATA CI_END="0.8293718633829845" CI_START="0.30143294104559687" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.08125070225483523" LOG_CI_START="-0.5208092890731272" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-03-16 14:52:47 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.2581988897471611" STUDY_ID="STD-Laeijendecker-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.06666666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="29" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:53:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus cyclosporin</NAME>
<DICH_DATA CI_END="1.9022680464213546" CI_START="0.9638315375647794" EFFECT_SIZE="1.3540553666828559" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" LOG_CI_END="0.2792717128535647" LOG_CI_START="-0.01599886723768377" LOG_EFFECT_SIZE="0.13163642280794047" MODIFIED="2011-03-16 14:53:17 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.17344340035854341" STUDY_ID="STD-Yoke-2006" TOTAL_1="71" TOTAL_2="68" VAR="0.03008261312793398" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:29:57 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="143" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcineurin inhibitors</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcineurin inhib</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:55:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus cyclosporin</NAME>
<DICH_DATA CI_END="47.69355681225106" CI_START="0.8363644765041706" EFFECT_SIZE="6.315789473684211" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6784597117467872" LOG_CI_START="-0.07760442155719559" LOG_EFFECT_SIZE="0.8004276450947958" MODIFIED="2011-03-16 14:55:15 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.0315207645604128" STUDY_ID="STD-Conrotto-2006" TOTAL_1="19" TOTAL_2="20" VAR="1.0640350877192983" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="9" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:55:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol versus tacrolimus</NAME>
<DICH_DATA CI_END="0.8342467112203769" CI_START="0.0033204603209533324" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.07870549675187248" LOG_CI_START="-2.4788017051537854" LOG_EFFECT_SIZE="-1.278753600952829" MODIFIED="2011-03-16 14:55:57 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.4098283934831244" STUDY_ID="STD-Corrocher-2008" TOTAL_1="16" TOTAL_2="16" VAR="1.9876160990712075" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:57:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus tacrolimus</NAME>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-03-16 14:57:06 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Laeijendecker-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="19" I2="0.0" ID="CMP-002.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:57:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus cyclosporin</NAME>
<DICH_DATA CI_END="0.48790018963167414" CI_START="0.0468711326652813" EFFECT_SIZE="0.15122312824314307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.3116690130909031" LOG_CI_START="-1.3290945514011077" LOG_EFFECT_SIZE="-0.8203817822460054" MODIFIED="2011-03-16 14:57:37 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.5976407975410539" STUDY_ID="STD-Yoke-2006" TOTAL_1="71" TOTAL_2="68" VAR="0.35717452288550705" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.06.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-16 14:57:56 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Triamcinolone versus pimecrolimus</NAME>
<DICH_DATA CI_END="4.1031984352603565" CI_START="0.0108617464979463" EFFECT_SIZE="0.2111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6131225204411241" LOG_CI_START="-1.9641003374141157" LOG_EFFECT_SIZE="-0.6754889084864959" MODIFIED="2011-03-16 14:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Gorouhi-2007" TOTAL_1="17" TOTAL_2="18" VAR="2.291812865497076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-04-07 13:40:51 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Steroid A vs steroid B</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-04-07 13:40:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.24" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Steroid A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroid A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Steroid B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" MODIFIED="2011-03-16 09:40:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetsol ointment (0.025%) versus clobetasol ointment (0.05%)</NAME>
<CONT_DATA CI_END="0.9020674782908876" CI_START="-1.4220674782908875" EFFECT_SIZE="-0.2599999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.13" MODIFIED="2011-03-10 15:43:12 +0000" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="1.51" SD_2="1.73" SE="0.5929024652785089" STUDY_ID="STD-Carbone-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" MODIFIED="2011-03-16 09:38:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol microspheres (0.025%)</NAME>
<CONT_DATA CI_END="2.857259930918138" CI_START="0.8027400690818618" EFFECT_SIZE="1.83" ESTIMABLE="YES" MEAN_1="2.77" MEAN_2="0.94" MODIFIED="2011-03-16 09:37:25 +0000" MODIFIED_BY="[Empty name]" ORDER="344" SD_1="2.42" SD_2="1.02" SE="0.5241218405139245" STUDY_ID="STD-Campisi-2004" TOTAL_1="27" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-04-07 12:26:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.52" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (mean clinical score)</NAME>
<GROUP_LABEL_1>Steroid A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroid A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Steroid B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" MODIFIED="2011-03-10 15:45:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol ointment (0.05%)</NAME>
<CONT_DATA CI_END="1.200026292031754" CI_START="-0.260026292031754" EFFECT_SIZE="0.47" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="1.8" MODIFIED="2010-02-02 11:32:40 +0000" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="1.03" SD_2="1.01" SE="0.3724692381034081" STUDY_ID="STD-Carbone-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" MODIFIED="2011-04-07 12:26:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol (0.025%) ointment versus clobetasol microspheres (0.025%)</NAME>
<CONT_DATA CI_END="0.6146083718121557" CI_START="-0.6146083718121557" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" MODIFIED="2011-04-07 12:26:19 +0100" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="1.2" SD_2="0.9" SE="0.31358146203711296" STUDY_ID="STD-Campisi-2004" TOTAL_1="27" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-07 13:33:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="96" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Clinical improvement</NAME>
<GROUP_LABEL_1>Steroid A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid B</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid A</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 13:33:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol ointment (0.05%)</NAME>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2011-03-10 15:00:27 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Carbone-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="14" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 12:28:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol microspheres (0.025%)</NAME>
<DICH_DATA CI_END="1.3593445951013028" CI_START="0.7969271584825386" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.13332956473871105" LOG_CI_START="-0.0985813725998656" LOG_EFFECT_SIZE="0.017374096069422723" MODIFIED="2011-04-07 12:28:02 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.13622563257033407" STUDY_ID="STD-Campisi-2004" TOTAL_1="28" TOTAL_2="17" VAR="0.018557422969187665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 12:33:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Prednisolone tablets (5 mg) versus triamcinolone paste (0.1%)</NAME>
<DICH_DATA CI_END="1.3218003037817425" CI_START="0.6409716867396262" EFFECT_SIZE="0.9204545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.12116584734581941" LOG_CI_START="-0.19316115388885718" LOG_EFFECT_SIZE="-0.035997653271518895" MODIFIED="2011-03-10 14:39:24 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.1846372364689991" STUDY_ID="STD-Ghabanchi-2009" TOTAL_1="11" TOTAL_2="9" VAR="0.03409090909090909" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="20" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 12:30:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.05%) versus triamcinolone (0.1%) ointment</NAME>
<DICH_DATA CI_END="1.1082230343634267" CI_START="0.902345438591618" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.04462717270799123" LOG_CI_START="-0.04462717270799122" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-16 10:53:28 +0000" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.0524284443134834" STUDY_ID="STD-Rodstrom-1994" TOTAL_1="17" TOTAL_2="20" VAR="0.0027487417731320296" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="16" I2="0.0" ID="CMP-003.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 12:32:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Betamethasone (5 mg) versus triamcinolone (0.1%)</NAME>
<DICH_DATA CI_END="1.5069842391807473" CI_START="0.690385455235816" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.1781087102624586" LOG_CI_START="-0.1609083667386235" LOG_EFFECT_SIZE="0.008600171761917567" MODIFIED="2011-03-14 12:12:45 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.19914030919203185" STUDY_ID="STD-Malhotra-2008" TOTAL_1="25" TOTAL_2="24" VAR="0.03965686274509805" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-07 13:33:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Steroid A</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid B</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid A</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 13:33:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol ointment (0.05%)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-10 15:03:10 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.0" STUDY_ID="STD-Carbone-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 13:26:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.025%) versus clobetasol microspheres (0.025%)</NAME>
<DICH_DATA CI_END="12.400493239174942" CI_START="0.11890573765729266" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0934389599034993" LOG_CI_START="-0.9247971885034274" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2011-04-07 13:26:57 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.1855219040042868" STUDY_ID="STD-Campisi-2004" TOTAL_1="28" TOTAL_2="17" VAR="1.4054621848739495" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="6" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 13:31:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Betamethasone (5 mg) versus triamcinolone (0.1%)</NAME>
<DICH_DATA CI_END="4.8630326266903765" CI_START="1.03178415305324" EFFECT_SIZE="2.24" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6869071833136144" LOG_CI_START="0.013588853354711408" LOG_EFFECT_SIZE="0.35024801833416286" MODIFIED="2011-03-10 15:38:10 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.3955105199973465" STUDY_ID="STD-Malhotra-2008" TOTAL_1="25" TOTAL_2="24" VAR="0.15642857142857142" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-07 13:31:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol ointment (0.05%) versus triamcinolone (0.1%) ointment</NAME>
<DICH_DATA CI_END="127.32047017394626" CI_START="0.38485563187958544" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1048982337313515" LOG_CI_START="-0.4147021537028377" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-04-04 15:27:18 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Rodstrom-1994" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-06-15 09:07:48 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Adjunctive anti-fungal treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2011-04-04 16:35:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (mean score)</NAME>
<GROUP_LABEL_1>Steroid plus antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid plus antifungal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" MODIFIED="2011-03-14 11:23:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol + miconazole versus clobetasol + placebo</NAME>
<CONT_DATA CI_END="1.2384942885116266" CI_START="-1.638494288511626" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.4" MODIFIED="2011-03-14 11:19:04 +0000" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="1.8" SD_2="2.2" SE="0.7339391437078873" STUDY_ID="STD-Lodi-2007" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2011-06-15 09:07:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.56" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (area of ulceration)</NAME>
<GROUP_LABEL_1>Steroid plus antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid plus antifungal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.01" MODIFIED="2011-03-14 11:19:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol + miconazole versus clobetasol + placebo</NAME>
<CONT_DATA CI_END="14.588430083689422" CI_START="-2.5884300836894223" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="13.3" MODIFIED="2011-03-14 11:19:26 +0000" MODIFIED_BY="[Empty name]" ORDER="75" SD_1="12.1" SD_2="11.9" SE="4.381932602554874" STUDY_ID="STD-Lodi-2007" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-21 09:27:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Clinical improvement</NAME>
<GROUP_LABEL_1>Steroid plus antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroid alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours S + antifungal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="15" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-21 09:27:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Dexamethasone + mycostatin versus dexamethasone alone</NAME>
<DICH_DATA CI_END="1.6058485200279822" CI_START="0.9348184674990674" EFFECT_SIZE="1.2252252252252251" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" LOG_CI_END="0.20570457580024976" LOG_CI_START="-0.029272716633129636" LOG_EFFECT_SIZE="0.08821592958356005" MODIFIED="2011-03-14 11:21:12 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.13802682473172373" STUDY_ID="STD-Wei-2003" TOTAL_1="37" TOTAL_2="20" VAR="0.01905140434552198" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:36:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Candidosis</NAME>
<GROUP_LABEL_1>Steroid plus Antifungal</GROUP_LABEL_1>
<GROUP_LABEL_2>Steroid alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours S + antifungal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-14 11:22:34 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clobetasol + miconazole versus clobetasol + placebo</NAME>
<DICH_DATA CI_END="1.511358498056095" CI_START="0.00546823458533967" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.17936749230765675" LOG_CI_START="-2.2621528626241068" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-03-14 11:22:34 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Lodi-2007" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-06-15 09:08:03 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Treatment A versus treatment B</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:36:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in pain</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment B</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment A</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-10 15:50:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone plus curcuminoids versus prednisone + placebo</NAME>
<DICH_DATA CI_END="1.3774977192293199" CI_START="0.6901100355591543" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.1390908884480035" LOG_CI_START="-0.16108165705092992" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2011-03-10 15:50:37 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.17632283910413762" STUDY_ID="STD-Chainani_x002d_Wu-2007" TOTAL_1="16" TOTAL_2="12" VAR="0.031089743589743604" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2011-04-04 16:36:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain score</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.01" MODIFIED="2011-03-14 11:19:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>BCG-PSN versus triamcinolone</NAME>
<CONT_DATA CI_END="0.15131994268984905" CI_START="-1.331319942689849" EFFECT_SIZE="-0.59" ESTIMABLE="YES" MEAN_1="0.93" MEAN_2="1.52" MODIFIED="2011-03-14 11:19:47 +0000" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="1.05" SD_2="1.61" SE="0.3782314106469742" STUDY_ID="STD-Xiong-2009" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2011-06-15 09:08:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="47.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Signs (area of ulceration)</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" MODIFIED="2011-03-10 15:52:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>BCG-PSN versus triamcinolone</NAME>
<CONT_DATA CI_END="5.999493050266592" CI_START="-17.599493050266595" EFFECT_SIZE="-5.800000000000001" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="7.48" MODIFIED="2010-02-09 13:13:09 +0000" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="3.19" SD_2="29.95" SE="6.0202601391349475" STUDY_ID="STD-Xiong-2009" TOTAL_1="28" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-01 11:35:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Clinical improvement</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment B</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment A</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-14 11:23:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Western + Chinese meds versus western meds</NAME>
<DICH_DATA CI_END="1.9151427792978395" CI_START="1.0066223075512901" EFFECT_SIZE="1.3884615384615384" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.28220115739063567" LOG_CI_START="0.0028665504790442086" LOG_EFFECT_SIZE="0.14253385393483994" MODIFIED="2011-03-10 17:06:51 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.1640825308284734" STUDY_ID="STD-Xu-2002" TOTAL_1="20" TOTAL_2="19" VAR="0.026923076923076925" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="22" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-01 11:35:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>BCG-PSN versus triamcinolone</NAME>
<DICH_DATA CI_END="1.2067787982466927" CI_START="0.8117291175788744" EFFECT_SIZE="0.9897360703812317" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.08162767150182967" LOG_CI_START="-0.09058887515273766" LOG_EFFECT_SIZE="-0.004480601825453991" MODIFIED="2011-04-01 11:35:06 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.1011608519905475" STUDY_ID="STD-Xiong-2009" TOTAL_1="31" TOTAL_2="25" VAR="0.010233517975453459" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:37:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-03-10 15:53:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>BCG-PSN versus triamcinolone</NAME>
<DICH_DATA CI_END="6.687358926726147" CI_START="0.21881874069130647" EFFECT_SIZE="1.2096774193548387" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.825254633460596" LOG_CI_START="-0.6599154856737036" LOG_EFFECT_SIZE="0.08266957389344619" MODIFIED="2010-03-30 16:38:00 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.8723962796901441" STUDY_ID="STD-Xiong-2009" TOTAL_1="31" TOTAL_2="25" VAR="0.7610752688172042" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-06-15 11:18:30 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-06-15 11:18:30 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUgAAARiCAIAAABJefmTAAA6x0lEQVR42u3dv44kRdrF4ZJwMMYY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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-06-15 11:18:30 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-07-30 14:16:54 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2011-06-10 11:35:44 +0100" MODIFIED_BY="Anne Littlewood">
<APPENDIX ID="APP-01" MODIFIED="2011-06-10 11:35:44 +0100" MODIFIED_BY="Anne Littlewood" NO="1">
<TITLE MODIFIED="2011-06-10 11:31:34 +0100" MODIFIED_BY="Anne Littlewood">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-10 11:35:44 +0100" MODIFIED_BY="Anne Littlewood">
<P>1.         LICHEN PLANUS, ORAL/<BR/>2.         ("lichen planus" and oral).mp.<BR/>3.         ("lichen planus" and mouth).mp.<BR/>4.         (OLP and mouth).mp.<BR/>5.         or/1-4</P>
<P>The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of <I>The Cochrane Handbook for Systematic Reviews of Interventions, </I>Version 5.1.0 [updated March 2011] (Higgins 2011).</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-06-10 11:32:57 +0100" MODIFIED_BY="Anne Littlewood" NO="2">
<TITLE MODIFIED="2011-06-10 11:32:43 +0100" MODIFIED_BY="Anne Littlewood">The Cochrane Oral Health Group Register Search Strategy  </TITLE>
<APPENDIX_BODY MODIFIED="2011-06-10 11:32:57 +0100" MODIFIED_BY="Anne Littlewood">
<P>(("lichen planus" OR lichen-planus OR OLP) AND (oral OR mucosa* OR mouth))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-06-10 11:33:22 +0100" MODIFIED_BY="Anne Littlewood" NO="3">
<TITLE MODIFIED="2011-06-10 11:33:08 +0100" MODIFIED_BY="Anne Littlewood">CENTRAL SEARCH STRATEGY</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-10 11:33:22 +0100" MODIFIED_BY="Anne Littlewood">
<P>#1        MeSH descriptor Lichen Planus, Oral this term only<BR/>#2        ("lichen planus" in All Text and oral in All Text)<BR/>#3        ("lichen planus" in All Text and mouth in All Text)<BR/>#4        (OLP in All Text and mouth in All Text)<BR/>#5        (#1 or #2 or #3 or #4)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-06-10 11:34:07 +0100" MODIFIED_BY="Anne Littlewood" NO="4">
<TITLE MODIFIED="2011-06-10 11:33:32 +0100" MODIFIED_BY="Anne Littlewood">EMBASE via OVID SEARCH STRATEGY</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-10 11:34:07 +0100" MODIFIED_BY="Anne Littlewood">
<P>1.         LICHEN PLANUS, ORAL/<BR/>2.         ("lichen planus" and oral).mp.<BR/>3.         ("lichen planus" and mouth).mp.<BR/>4.         (OLP and mouth).mp.<BR/>5.         or/1-4</P>
<P>The above subject search was linked to the Cochrane Oral Health Group filter for EMBASE via OVID:</P>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>16. HUMAN/<BR/>17. 16 and 15<BR/>18. 15 not 17<BR/>19. 14 not 18</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-07-30 14:16:54 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>